<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US6143864 - Peptides - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Peptides"><meta name="DC.contributor" content="Deborah DeFeo-Jones" scheme="inventor"><meta name="DC.contributor" content="Dong-Mei Feng" scheme="inventor"><meta name="DC.contributor" content="Victor M. Garsky" scheme="inventor"><meta name="DC.contributor" content="Raymond E. Jones" scheme="inventor"><meta name="DC.contributor" content="Allen I. Oliff" scheme="inventor"><meta name="DC.contributor" content="Merck &amp; Co., Inc." scheme="assignee"><meta name="DC.date" content="1995-6-6" scheme="dateSubmitted"><meta name="DC.description" content="Oligopeptides which comprise amino acid sequences that are recognized and proteolytically cleaved by free prostate specific antigen (PSA) are described. Also described are assays which comprise such oligopeptides useful for determining free PSA protease activity in vitro and in vivo. Therapeutic agents which comprise conjugates of such oligopeptides and known cytotoxic agents are also described."><meta name="DC.date" content="2000-11-7" scheme="issued"><meta name="DC.relation" content="EP:0126344:A2" scheme="references"><meta name="DC.relation" content="EP:0554708:A1" scheme="references"><meta name="DC.relation" content="EP:0590530:A2" scheme="references"><meta name="DC.relation" content="FR:2678274" scheme="references"><meta name="DC.relation" content="US:4277466" scheme="references"><meta name="DC.relation" content="US:4296105" scheme="references"><meta name="DC.relation" content="US:4388305" scheme="references"><meta name="DC.relation" content="US:4446122" scheme="references"><meta name="DC.relation" content="US:4703107" scheme="references"><meta name="DC.relation" content="US:4753984" scheme="references"><meta name="DC.relation" content="US:4828831" scheme="references"><meta name="DC.relation" content="US:4870162" scheme="references"><meta name="DC.relation" content="US:5024835" scheme="references"><meta name="DC.relation" content="US:5030620" scheme="references"><meta name="DC.relation" content="US:5220001" scheme="references"><meta name="DC.relation" content="US:5288612" scheme="references"><meta name="DC.relation" content="US:5349066" scheme="references"><meta name="DC.relation" content="US:5391723" scheme="references"><meta name="DC.relation" content="US:5599686" scheme="references"><meta name="DC.relation" content="US:5866679" scheme="references"><meta name="DC.relation" content="WO:1992001936:A1" scheme="references"><meta name="DC.relation" content="WO:1994010343:A1" scheme="references"><meta name="DC.relation" content="WO:1994020114:A1" scheme="references"><meta name="DC.relation" content="WO:1995030758:A1" scheme="references"><meta name="DC.relation" content="WO:1996005863:A1" scheme="references"><meta name="citation_reference" content="Anal. Biochem., vol. 193, pp. 248 255 (1991), by Harnois Pontoni, et al."><meta name="citation_reference" content="Anal. Biochem., vol. 193, pp. 248-255 (1991), by Harnois-Pontoni, et al."><meta name="citation_reference" content="Barnett, C.J., et al., Structure Activity Relationships of Dimeric Catharanthus Alkaloids. 1. Deacetylyinblastine Amide (Vindesine) Sulfate, Jour. Med. Chem., vol. 21, No. 1 (1978)."><meta name="citation_reference" content="Barnett, C.J., et al., Structure-Activity Relationships of Dimeric Catharanthus Alkaloids. 1. Deacetylyinblastine Amide (Vindesine) Sulfate, Jour. Med. Chem., vol. 21, No. 1 (1978)."><meta name="citation_reference" content="Eur. J. Biochem, vol. 95, pp. 115 119 (1979), by Pozsgay, et al."><meta name="citation_reference" content="Eur. J. Biochem, vol. 95, pp. 115-119 (1979), by Pozsgay, et al."><meta name="citation_reference" content="Eur. J. Biochem., vol. 194, pp. 755 763 (1990), by Christensson, et al."><meta name="citation_reference" content="Eur. J. Biochem., vol. 194, pp. 755-763 (1990), by Christensson, et al."><meta name="citation_reference" content="J. Med. Chem, vol. 26, pp. 633 638 (1983), by Chakravarty, et al."><meta name="citation_reference" content="J. Med. Chem, vol. 26, pp. 633-638 (1983), by Chakravarty, et al."><meta name="citation_reference" content="J. Med. Chem., vol. 34, pp. 3029 3035 (1991), by Mayer, et al."><meta name="citation_reference" content="J. Med. Chem., vol. 34, pp. 3029-3035 (1991), by Mayer, et al."><meta name="citation_reference" content="J. of Med. Chem, vol. 26, No. 5, pp. 638 644 (1983), by Chakravarty, et al."><meta name="citation_reference" content="J. of Med. Chem, vol. 26, No. 5, pp. 638-644 (1983), by Chakravarty, et al."><meta name="citation_reference" content="Lilja, H. and Lundwall, A., &quot;Molecular cloning of epididymal and seminal vesicular transcripts encoding a semenogelin-related protein,&quot; Proc. Natl. Acad, Sci. USA, Biochemistry, vol. 89, pp. 4559-4563 (1992)."><meta name="citation_reference" content="Lilja, H. and Lundwall, A., Molecular cloning of epididymal and seminal vesicular transcripts encoding a semenogelin related protein, Proc. Natl. Acad, Sci. USA, Biochemistry , vol. 89, pp. 4559 4563 (1992)."><meta name="citation_reference" content="Lilja, H., et al., &quot;Semenogelin, the Predominant Protein in Human Semen,&quot; The Jour. of Biol. Chem., vol. 264, No. 3, pp. 1894-1900 (1989)."><meta name="citation_reference" content="Lilja, H., et al., Semenogelin, the Predominant Protein in Human Semen, The Jour. of Biol. Chem., vol. 264, No. 3, pp. 1894 1900 (1989)."><meta name="citation_reference" content="Proc. Natl. Acad. Sci. USA, vol. 83, pp. 3166 3170 (1986) Biochemistry, by Watt, et al."><meta name="citation_reference" content="Proc. Natl. Acad. Sci. USA, vol. 83, pp. 3166-3170 (1986) Biochemistry, by Watt, et al."><meta name="citation_reference" content="Rao, K.S.P.B., et al., Vinblastin 23 oyl Amino Acid Derivatives: Chemistry, Physiochemical Data, Toxicity, and Antitumor Activities against P388 and L1210 Leukemias, Jour. Med. Chem. , vol. 28, pp. 1079 1088 (1985)."><meta name="citation_reference" content="Rao, K.S.P.B., et al., Vinblastin-23-oyl Amino Acid Derivatives: Chemistry, Physiochemical Data, Toxicity, and Antitumor Activities against P388 and L1210 Leukemias, Jour. Med. Chem., vol. 28, pp. 1079-1088 (1985)."><meta name="citation_reference" content="Trail, P.A., et al., Cure of Xenografted Human Carcinomas by BR96 Doxorubicin Immunoconjugates, Science, vol. 261, pp. 212 215 (1993)."><meta name="citation_reference" content="Trail, P.A., et al., Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates, Science, vol. 261, pp. 212-215 (1993)."><meta name="citation_reference" content="Willner, D. et al., (6 Maleimidocaproyl)hydrazone of Doxorubicin A New Derivative for the Preparation of Immunoconjugates of Doxorubicin, Bioconjugate Chem., vol. 4, pp. 521 527 (1993)."><meta name="citation_reference" content="Willner, D. et al., (6-Maleimidocaproyl)hydrazone of Doxorubicin--A New Derivative for the Preparation of Immunoconjugates of Doxorubicin, Bioconjugate Chem., vol. 4, pp. 521-527 (1993)."><meta name="citation_reference" content="Yu, H., et al., Immunoreactive Prostate Specific Antigen Levels in Female and Male Breast Tumors and its Association with Steroid Hormone Receptors and Patient Age, Clinical Biochemistry , vol. 27, pp. 75 79 (1994)."><meta name="citation_reference" content="Yu, H., et al., Immunoreactive Prostate-Specific Antigen Levels in Female and Male Breast Tumors and its Association with Steroid Hormone Receptors and Patient Age, Clinical Biochemistry, vol. 27, pp. 75-79 (1994)."><meta name="citation_patent_number" content="US:6143864"><meta name="citation_patent_application_number" content="US:08/468,161"><link rel="canonical" href="http://www.google.com/patents/US6143864"/><meta property="og:url" content="http://www.google.com/patents/US6143864"/><meta name="title" content="Patent US6143864 - Peptides"/><meta name="description" content="Oligopeptides which comprise amino acid sequences that are recognized and proteolytically cleaved by free prostate specific antigen (PSA) are described. Also described are assays which comprise such oligopeptides useful for determining free PSA protease activity in vitro and in vivo. Therapeutic agents which comprise conjugates of such oligopeptides and known cytotoxic agents are also described."/><meta property="og:title" content="Patent US6143864 - Peptides"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("7SruU-WDPKKlsATOk4DIBg"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("PRT"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("7SruU-WDPKKlsATOk4DIBg"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("PRT"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us6143864?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US6143864"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=r7hRBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS6143864&amp;usg=AFQjCNGnzTWMrXUHjNcOUbocaKXcM6vdfQ" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US6143864.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US6143864.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US6143864" style="display:none"><span itemprop="description">Oligopeptides which comprise amino acid sequences that are recognized and proteolytically cleaved by free prostate specific antigen (PSA) are described. Also described are assays which comprise such oligopeptides useful for determining free PSA protease activity in vitro and in vivo. Therapeutic agents...</span><span itemprop="url">http://www.google.com/patents/US6143864?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US6143864 - Peptides</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US6143864 - Peptides" title="Patent US6143864 - Peptides"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US6143864 A</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 08/468,161</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Nov 7, 2000</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Jun 6, 1995</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Jun 28, 1994</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Lapsed</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CA2192957A1">CA2192957A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1156964A">CN1156964A</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69528064D1">DE69528064D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0771209A2">EP0771209A2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0771209A4">EP0771209A4</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0771209B1">EP0771209B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO1996000503A1">WO1996000503A1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">08468161, </span><span class="patent-bibdata-value">468161, </span><span class="patent-bibdata-value">US 6143864 A, </span><span class="patent-bibdata-value">US 6143864A, </span><span class="patent-bibdata-value">US-A-6143864, </span><span class="patent-bibdata-value">US6143864 A, </span><span class="patent-bibdata-value">US6143864A</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Deborah+DeFeo-Jones%22">Deborah DeFeo-Jones</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Dong-Mei+Feng%22">Dong-Mei Feng</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Victor+M.+Garsky%22">Victor M. Garsky</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Raymond+E.+Jones%22">Raymond E. Jones</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Allen+I.+Oliff%22">Allen I. Oliff</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Merck+%26+Co.,+Inc.%22">Merck & Co., Inc.</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US6143864.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6143864.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6143864.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (25),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (28),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (17),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (27),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (10)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/6143864&usg=AFQjCNEmbzIG-_Lp0ySAmvCE7IRQivYwoA">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D6143864&usg=AFQjCNEEg3WWr0HEtGZpjLez1FL3Ysmyvw">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D6143864A%26KC%3DA%26FT%3DD&usg=AFQjCNE5jPBisXbim23-jv4RQ8pVZfI8kA">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT54666628" lang="EN" load-source="patent-office">Peptides</invention-title></span><br><span class="patent-number">US 6143864 A</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA38150728" lang="EN" load-source="patent-office"> <div class="abstract">Oligopeptides which comprise amino acid sequences that are recognized and proteolytically cleaved by free prostate specific antigen (PSA) are described. Also described are assays which comprise such oligopeptides useful for determining free PSA protease activity in vitro and in vivo. Therapeutic agents which comprise conjugates of such oligopeptides and known cytotoxic agents are also described.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(9)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6143864-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6143864-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6143864-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6143864-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6143864-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6143864-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6143864-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6143864-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6143864-5.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6143864-5.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6143864-6.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6143864-6.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6143864-7.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6143864-7.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6143864-8.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6143864-8.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6143864-9.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6143864-9.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(8)</span></span></div><div class="patent-text"><div mxw-id="PCLM59584881" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>What is claimed is:</claim-statement> <div class="claim"> <div num="1" class="claim">
      <div class="claim-text">1. A conjugate which is useful for the treatment of prostate cancer which comprises a cytotoxic agent attached to a oligopeptide, wherein the oligopeptide comprises a sequence of amino acids that is recognized and selectively proteolytically cleaved by free prostate specific antigen and provided that the oligopeptide does not comprise semenogelin I or semenogelin II, wherein the means of attachment is a covalent bond or a chemical linker.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="2" class="claim">
      <div class="claim-text">2. The conjugate according to claim 1 wherein the cytotoxic agent is a member of a class of cytotoxic agents selected from the following classes:<div class="claim-text">a) anthracycline family of drugs,</div> <div class="claim-text">b) the vinca alkaloid drugs,</div> <div class="claim-text">c) the mitomycins,</div> <div class="claim-text">d) the bleomycins,</div> <div class="claim-text">e) the cytotoxic nucleosides,</div> <div class="claim-text">f) the pteridine family of drugs,</div> <div class="claim-text">g) diynenes,</div> <div class="claim-text">h) estramustine,</div> <div class="claim-text">i) cyclophosphamide, and</div> <div class="claim-text">h) the podophyllotoxins.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="3" class="claim">
      <div class="claim-text">3. The conjugate according to claim 1 wherein the cytotoxic agent is selected from the following cytotoxic agents:<div class="claim-text">a) doxorubicin,</div> <div class="claim-text">b) carminomycin,</div> <div class="claim-text">c) daunorubicin,</div> <div class="claim-text">d) aminopterin,</div> <div class="claim-text">e) methotrexate,</div> <div class="claim-text">f) methopterin,</div> <div class="claim-text">g) dichloro-methotrexate,</div> <div class="claim-text">h) mitomycin C,</div> <div class="claim-text">i) porfiromycin,</div> <div class="claim-text">j) 5-fluorouracil,</div> <div class="claim-text">k) 6-mercaptopurine,</div> <div class="claim-text">l) cytosine arabinoside,</div> <div class="claim-text">m) podophyllotoxin,</div> <div class="claim-text">n) etoposide,</div> <div class="claim-text">o) etoposide phosphate,</div> <div class="claim-text">p) melphalan,</div> <div class="claim-text">q) vinblastine,</div> <div class="claim-text">r) vincristine,</div> <div class="claim-text">s) leurosidine,</div> <div class="claim-text">t) vindesine,</div> <div class="claim-text">u) estramustine,</div> <div class="claim-text">v) cisplatin,</div> <div class="claim-text">w) cyclophosphamide, and</div> <div class="claim-text">x) leurosine.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="4" class="claim">
      <div class="claim-text">4. The conjugate according to claim 1 wherein the cytotoxic agent is selected from doxorubicin and vinblastine or a cytotoxic derivative thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="5" class="claim">
      <div class="claim-text">5. The conjugate according to claim 1 wherein the cytotoxic agent is doxorubicin or a cytotoxic derivative thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="6" class="claim">
      <div class="claim-text">6. The conjugate according to claim 5 of the formula I: ##STR23## wherein: oligopeptide is an oligopeptide which is specifically recognized by the free prostate specific antigen (PSA) and is capable of being proteolytically cleaved by the enzymatic activity of the free prostate specific antigen;<div class="claim-text">X<sub>L</sub> is absent or is an amino acid selected from:<div class="claim-text">a) phenylalanine,</div> <div class="claim-text">b) leucine,</div> <div class="claim-text">c) valine,</div> <div class="claim-text">d) isoleucine,</div> <div class="claim-text">e) (2-naphthyl)alanine,</div> <div class="claim-text">f) cyclohexylalanine,</div> <div class="claim-text">g) diphenylalanine,</div> <div class="claim-text">h) norvaline, and</div> <div class="claim-text">j) norleucine;</div> </div> <div class="claim-text">R is hydrogen or --(C‚ïêO)R<sup>1</sup> ; and</div> <div class="claim-text">R<sup>1</sup> is C<sub>1</sub> -C<sub>6</sub> -alkyl or aryl.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="7" class="claim">
      <div class="claim-text">7. The conjugate according to claim 6 wherein:<div class="claim-text">oligopeptide is an oligomer that comprises an amino acid sequence selected from:<div class="claim-text"> <pre xml:space="preserve" listing-type="equation">a) AsnLysIleSerTyrGln|Ser,                        (SEQ.ID.NO.: 13)</pre> </div> <div class="claim-text"> <pre xml:space="preserve" listing-type="equation">b) LysIleSerTyrGln|Ser,                           (SEQ.ID.NO.: 14)</pre> </div> <div class="claim-text"> <pre xml:space="preserve" listing-type="equation">c) GlyGluAsnGlyValGlnLysAspValSerGlnXaaSerIleTyr|SerGlnThrGlu, (SEQ.ID.NO.: 15)</pre> </div> <div class="claim-text"> <pre xml:space="preserve" listing-type="equation">d) GlyLysGlyIleSerSerGlnTyr|SerAsnThrGluGluArgLeu, (SEQ.ID.NO.: 2)</pre> </div> <div class="claim-text"> <pre xml:space="preserve" listing-type="equation">e) AsnLysIleSerTyrTyr|Ser,                        (SEQ.ID.NO.: 127)</pre> </div> <div class="claim-text"> <pre xml:space="preserve" listing-type="equation">f) AsnLysAlaSerTyrGln|Ser,                        (SEQ.ID.NO.: 128)</pre> </div> <div class="claim-text"> <pre xml:space="preserve" listing-type="equation">g) SerTyrGln|SerSer, and                          (SEQ.ID.NO.: 129)</pre> </div> <div class="claim-text"> <pre xml:space="preserve" listing-type="equation">h) hArgTyrGln|SerSer;                             (SEQ.ID.NO.: 141)</pre> </div> <div class="claim-text">wherein hArg is homoarginine and Xaa is any natural amino acid;</div> </div> <div class="claim-text">X<sub>L</sub> is absent or is an amino acid selected from:<div class="claim-text">a) leucine,</div> <div class="claim-text">b) isoleucine, and</div> <div class="claim-text">d) valine; and</div> </div> <div class="claim-text">R is acetyl, pivaloyl or benzoyl.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="8" class="claim">
      <div class="claim-text">8. The conjugate according to claim 5 which is selected from: ##STR24## wherein X is: ##STR25##</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES67560819" lang="EN" load-source="patent-office" class="description">
    <heading>RELATED APPLICATION</heading> <p>The present patent application is a Continuation-in-Part application of application Ser. No. 08/404,833, filed Mar. 15, 1995, now abandoned, which itself is a Continuation-in-Part application of application Ser. No. 08/267,092, filed Jun. 28, 1994, now U.S. Pat. No. 5,599,686.</p>
    <heading>BACKGROUND OF THE INVENTION</heading> <p>In 1994 cancer of the prostate gland is expected to be diagnosed in 200,000 men in the U.S. and 38,000 American males will die from this disease (Garnick, M. B. (1994). The Dilemmas of Prostate Cancer. Scientific American, April:72-81). Thus, prostate cancer is the most frequently diagnosed malignancy (other than that of the skin) in U.S. men and the second leading cause of cancer-related deaths (behind lung cancer) in that group.</p>
    <p>Prostate specific Antigen (PSA) is a single chain 33 kDa glycoprotein that is produced almost exclusively by the human prostate epithelium and occurs at levels of 0.5 to 2.0 mg/ml in human seminal fluid (Nadji, M., Taber, S. Z., Castro, A., et al. (1981) Cancer 48:1229;Papsidero, L., Kuriyama, M., Wang, M., et al. (1981). JNCI 66:37; Qui, S. D., Young, C. Y. F., Bihartz, D. L., et al. (1990), J. Urol. 144:1550; Wang, M. C., Valenzuela, L. A., Murphy, G. P., et al. (1979). Invest. Urol. 17:159). The single carbohydrate unit is attached at asparagine residue number 45 and accounts for 2 to 3 kDa of the total molecular mass. PSA is a protease with chymotrypsin-like specificity (Christensson, A., Laurell, C. B., Lilja, H. (1990). Eur. J. Biochem. 194:755-763). It has been shown that PSA is mainly responsible for dissolution of the gel structure formed at ejaculation by proteolysis of the major proteins in the sperm entrapping gel, Semenogelin I and Semenogelin II, and fibronectin (Lilja, H. (1985). J. Clin. Invest. 76:1899; Lilja, H., Oldbring, J., Rannevik, G., et al. (1987). J. Clin. Invest. 80:281; McGee, R. S., Herr, J. C. (1988). Biol. Reprod. 39:499). The PSA mediated proteolysis of the gel-forming proteins generates several soluble Semenogelin I and Semenogelin II fragments and soluble fibronectin fragments with liquefaction of the ejaculate and release of progressively motile spermatoza (Lilja, H., Laurell, C. B. (1984). Scand. J. Clin. Lab. Invest. 44:447; McGee, R. S., Herr, J. C. (1987). Biol. Reprod. 37:431). Furthermore, PSA may proteolytically degrade IGFBP-3 (insulin-like growth factor binding protein 3) allowing IGF to stimulate specifically the growth of PSA secreting cells (Cohen et al., (1992) J. Clin. Endo. &amp; Meta. 75:1046-1053).</p>
    <p>PSA complexed to alpha 1-antichymotrypsin is the predominant molecular form of serum PSA and may account for up to 95% of the detected serum PSA (Christensson, A., Bjork, T., Nilsson, O., et al. (1993). J. Urol. 150:100-105; Lilja, H., Christensson, A., Dahlen, U. (1991). Clin. Chem. 37:1618-1625; Stenman, U. H., Leinoven, J., Alfthan, H., et al. (1991). Cancer Res. 51:222-226). The prostatic tissue (normal, benign hyperplastic, or malignant tissue) is implicated to predominantly release the mature, enzymatically active form of PSA, as this form is required for complex formation with alpha 1-antichymotrypsin (Mast, A. E., Enghild, J. J., Pizzo, S. V., et al. (1991). Biochemistry 30:1723-1730; Perlmutter, D. H., Glover, G. I., Rivetna, M., et al. (1990). Proc. Natl. Acad. Sci. USA 87:3753-3757). Therefore, in the microenvironment of prostatic PSA secreting cells the PSA is believed to be processed and secreted in its mature enzymatically active form not complexed to any inhibitory molecule. PSA also forms stable complexes with alpha 2-macroglobulin, but as this results in encapsulation of PSA and complete loss of the PSA epitopes, the in vivo significance of this complex formation is unclear. A free, noncomplexed form of PSA constitutes a minor fraction of the serum PSA (Christensson, A., Bjork, T., Nilsson, O., et al. (1993). J. Urol. 150:100-105; Lilja, H., Christensson, A., Dahlen, U. (1991). Clin. Chem. 37:1618-1625). The size of this form of serum PSA is similar to that of PSA in seminal fluid (Lilja, H., Christensson, A., Dahlen, U. (1991). Clin. Chem. 37:1618-1625) but it is yet unknown as to whether the free form of serum PSA may be a zymogen; an internally cleaved, inactive form of mature PSA; or PSA manifesting enzyme activity. However, it seems unlikely that the free form of serum PSA manifests enzyme activity, since there is considerable (100 to 1000 fold) molar excess of both unreacted alpha 1-antichymotrypsin and alpha 2-macroglobulin in serum as compared with the detected serum levels of the free 33 kDa form of PSA (Christensson, A., Bjork, T., Nilsson, O., et al. (1993). J. Urol. 150:100-105; Lilja, H., Christensson, A., Dahlen, U. (1991). Clin. Chem. 37:1618-1625).</p>
    <p>Serum measurements of PSA are useful for monitoring the treatment of adenocarcinoma of the prostate (Duffy, M. S. (1989). Ann. Clin. Biochem. 26:379-387; Brawer, M. K. and Lange, P. H. (1989). Urol. Suppl. 5:11-16; Hara, M. and Kimura, H. (1989). J. Lab. Clin. Med. 113:541-548), although above normal serum concentrations of PSA have also been reported in benign prostatic hyperplasia and subsequent to surgical trauma of the prostate (Lilja, H., Christensson, A., Dahlen, U. (1991). Clin. Chem. 37:1618-1625). Prostate metastases are also known to secrete immunologically reactive PSA since serum PSA is detectable at high levels in prostatectomized patients showing widespread metatstatic prostate cancer (Ford, T. F., Butcher, D. N., Masters, R. W., et al. (1985). Brit. J. Urology 57:50-55). Therefore, a cytotoxic compound that could be activated by the proteolytic activity of PSA should be prostate cell specific as well as specific for PSA secreting prostate metastases.</p>
    <p>Accordingly, it is the object of this invention to provide novel oligopeptides which selectively are enzymatically cleaved by active free prostate specific antigen (PSA).</p>
    <p>It is also the object of this invention to provide a quantitative assay for enzymatically active PSA which incorporates those novel oligopeptides.</p>
    <p>It is further the object of this invention to provide a novel anti-cancer composition useful for the treatment of prostate cancer which comprises those novel oligopeptides in conjugation with a cytotoxic agent.</p>
    <p>Another object of this invention is to provide a method of treating prostate cancer which comprises administration of novel anti-cancer composition.</p>
    <heading>SUMMARY OF THE INVENTION</heading> <p>The several points of cleavage where semenogelin I is selectively proteolytically cleaved by free PSA have been identified. Oligopeptides which comprise the amino acid sequences that are recognized and proteolytically cleaved by free prostate specific antigen (PSA) are described. Such oligopeptides are useful in assays-which can determine the free PSA protease activity in vitro and in vivo. Furthermore, such oligopeptides may be incorporated into therapeutic agents which comprise conjugates of such oligopeptides and known cytotoxic agents and which are useful in the treatment of prostatic cancer.</p>
    <heading>BRIEF DESCRIPTION OF THE FIGURES</heading> <p>FIGS. 1a and 1b: Primary Amino Acid Sequence of Semenogelin I: The primary amino acid sequence of Semenogelin I is shown. (SEQ.ID.NO.: 1) The PSA proteolytic cleavage sites ("CS") are shown (numbered in order of the relative affinity of a site towards PSA hydrolysis) and the protein fragments are numbered sequentially starting at the amino terminus.</p>
    <p>FIG. 2: Cleavage Affinity of Synthetic Oligopeptides: A nested set of synthetic oligopeptides was prepared and the oligopeptides were digested with enzymaticaaly active free PSA for various times. The results are shown. The following SEQ. ID. NOs. apply to the peptides listed in the Figure: peptide 1 - SEQ. ID. NO. 7; peptide 2 - SEQ. ID. NO. 8; peptide 3 - SEQ. ID. NO. 9; peptide 4 - SEQ. ID. NO. 3; peptide 5 - SEQ. ID. NO. 10; peptide 6 - SEQ. ID. NO. 11; peptide 7 - SEQ. ID. NO. 18; peptide 8 - SEQ. ID. NO. 17; peptide 9 - SEQ. ID. NO. 69; and peptide 10 - SEQ. ID. NO. 6;</p>
    <p>FIGS. 3a and 3b: Cleavage Affinity of Synthetic Oligopeptides: Synthetic oligopeptides were prepared and the oligopeptides were digested with enzymatically active free PSA for four (4) hours. The percentage of the oligopeptide that is cleaved in this period of time is listed. The results are shown in FIG. 4.</p>
    <p>FIG. 4: Cytotoxicity Data of Non-cleavable Oligopeptide-Doxorubicin Conjugates: The data of the figure shows comparative cytotoxicity of doxorubicin and a conjugate of doxorubicin covalently bound to an oligopeptide (Compound 12d) that does not contain the free PSA proteolytic cleavage site. The EC<sub>50</sub> for doxorubicin is 0.3 ŒºM, while the acetylated oligopeptide modified doxorubicin has an EC<sub>50</sub> that has been reduced by greater than 300 fold. This conjugate had no HPLC detectable contamination with unmodified doxorubicin. The oligopeptide alone had no detectable cell killing activity.</p>
    <p>FIG. 5: Cleavage Affinity of Oligopeptides in Conjugation with Doxorubicin by Free PSA In Vitro: Oligopeptides-doxorubicin conjugates were prepared and the conjugates were digested with enzymatically active free PSA for four (4) hours. The percentage conjugate that is enzymatically cleaved in the oligopeptide in this period of time is listed. The results are shown in the Figure.</p>
    <p>FIG. 6: Cleavage Affinity of Oligopeptides in Conjugation with Doxorubicin in Cell Conditioned Media: Oligopeptides-doxorubicin conjugates were reacted for four (4) hours with cell culture media that had been conditioned by exposure to LNCaP cells (which are known to secrete free PSA) or DuPRO cell (which do not secrete free PSA). The percentage conjugate that is enzymatically cleaved in the oligopeptide in this period of time is listed. The results are shown in the Figure.</p>
    <p>FIG. 7: Cytotoxicity Data of Cleavable Oligopeptide-Doxorubicin Conjugates:</p>
    <p>The data in the Figure shows cytotoxicity (as EC<sub>50</sub>) of conjugates of doxorubicin covalently bound to an oligopeptide that contain a free PSA proteolytic cleavage site against a cancer cell line that is known to secrete free PSA. Also shown for selected conjugates is the cytotoxicity of the conjugate against a cell line (DuPRO) which does not secrete free PSA.</p>
    <heading>DETAILED DESCRIPTION OF THE INVENTION</heading> <p>The present invention relates to novel oligopeptides which are specifically recognized by the free prostate specific antigen (PSA) and are capable of being proteolytically cleaved by the enzymatic activity of the free prostate specific antigen. Such oligopeptides include oligomers that comprise an amino acid sequence selected from:</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">a) AsnLysIleSerTyrGln|Ser,                        (SEQ.ID.NO.: 13)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">b) LysIleSerTyrGln|Ser,                           (SEQ.ID.NO.: 14)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">c) GlyGluAsnGlyValGlnLysAspValSerGlnXaaSerIleTyr|SerGlnThrGlu, (SEQ.ID.NO.: 15)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">d) GlyLysGlyIleSerSerGlnTyr|SerAsnThrGluGluArgLeu, (SEQ.ID.NO.: 2)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">e) AsnLysIleSerTyrTyr|Ser,                        (SEQ.ID.NO.: 127)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">f) AsnLysAlaSerTyrGln|Ser,                        (SEQ.ID.NO.: 128)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">g) SerTyrGln|SerSer;                              (SEQ.ID.NO.: 129)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">h) LysTyrGln|SerSer; and                          (SEQ.ID.NO.: 140)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">i) hArgTyrGln|SerSer;                             (SEQ.ID.NO.: 141)</pre>
    
    <p>wherein hArg is homoarginine and Xaa is any natural amino acid.</p>
    <p>In an embodiment of the instant invention, the oligopeptides include oligomers that comprise an amino acid sequence that is selected from:</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">a) AsnLysIleSerTyrGln|SerSer,                     (SEQ.ID.NO.: 16)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">b) AsnLysIleSerTyrGln|SerAla,                     (SEQ.ID.NO.: 130)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">c) AsnLysIleSerTyrGln|SerSerSer,                  (SEQ.ID.NO.: 17)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">d) AlaAsnLysIleSerTyrGln|SerSerSer,               (SEQ.ID.NO.: 18)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">e) LysIleSerTyrGln|SerSerSerThrGlu,               (SEQ.ID.NO.: 19)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">f) GlyGluAsnGlyValGlnLysAspValSerGlnArgSerIleTyr|SerGlnThrGlu, (SEQ.ID.NO.: 4)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">g) GlyGluAsnGlyValGlnLysAspValSerGlnSerSerIleTyr|SerGlnThrGlu, (SEQ.ID.NO.: 5)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">h) AlaAsnLysIleSerTyrTyr|Ser,                     (SEQ.ID.NO.: 131)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">i) AlaAsnLysAlaSerTyrGln|Ser,                     (SEQ.ID.NO.: 132)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">j) SerTyrGln|SerSerThr,                           (SEQ.ID.NO.: 133)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">k) SerTyrGln|SerSerSer,                           (SEQ.ID.NO.: 134)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">l) LysTyrGln|SerSerSer,                           (SEQ.ID.NO.: 142)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">m) hArgTyrGln|SerSerSer, and                      (SEQ.ID.NO.: 143)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">n) SerTyrGln|SerSerLeu.                           (SEQ.ID.NO.: 135)</pre>
    
    <p>In a more preferred embodiment of the instant invention, the oligopeptides include oligomers that comprise an amino acid sequence that is selected from:</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">a) AsnLysIleSerTyrGln |SerSerSerThr,              (SEQ.ID.NO.:10)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">b) AlaAsnLysIleSerTyrGln|SerAla,                  (SEQ.ID.NO.: 136)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">c) AsnLysIleSerTyrGln|SerSerSerThrGlu,            (SEQ.ID.NO.:3)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">d) AlaAsnLysIleSerTyrGln|SerSerSerThrGlu,         (SEQ.ID.NO.: 11)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">e) GlyGluAsnGlyValGlnLysAspValSerGlnArgSerIleTyr|SerGlnThrGlu, (SEQ.ID.NO.: 4)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">f) AlaAsnLysIleSerTyrTyr|SerSer,                  (SEQ.ID.NO.: 137)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">g) AlaAsnLysIleSerTyrTyr|SerAla,                  (SEQ.ID.NO.: 138)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">h) AlaAsnLysAlaSerTyrGln|SerAla,                  (SEQ.ID.NO.: 139)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">i) AlaSerTyrGln|SerSerLeu.                        (SEQ.ID.NO.: 94)</pre>
    
    <p>In a further embodiment of the instant invention, the oligopeptides include oligomers that comprise an amino acid sequence that is selected from:</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">a) GlyArgLysAlaAsnLysIleSerTyrGln|SerSerSerThrGluGluArgArg LeuHisTyrGlyGluAsnGly.                                    (SEQ.ID.NO.: 6)</pre>
    
    <p>The phrase "oligomers that comprise an amino acid sequence" as used hereinabove, and elsewhere in the Detailed Description of the Invention, describes oligomers of from about 6 to about 100 amino acids residues which include in their amino acid sequence the specific amino acid sequence decribed and which are therefore proteolytically cleaved within the amino acid sequence described by free PSA. Thus, for example, the following oligomer:</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlnLeuAspAsnLysIleSerTyrGln|SerSerSerThrHisGlnSerSer (SEQ.ID.NO.: 20)</pre>
    
    <p>comprises the amino acid sequence:</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">AsnLysIleSerTyrGln|SerSerSerThr                   (SEQ.ID.NO.:10)</pre>
    
    <p>and would therefore come within the instant invention. It is understood that such oligomers do not include semenogelin I and semenogelin II.</p>
    <p>It is also understood that the instant invention includes oligomers wherein the N-terminus amino acid or the C-terminus amino acid, or both terminus amino acids are modified. Such modifications include, but are not limited to, acylation of the amine group at the N-terminus and formation of an amide to replace the carboxylic acid at the C-terminus. Addition of such moieties may be performed during solid-phase synthesis of the oligomer; thus, attachment of the C-terminus amino acid to a solid phase resin may be through an amine which results in an amide moiety upon acidic cleavage of the oligomer from the resin. Thus the following compounds are considered "oligomers that comprise an amino acid sequence" as used hereinabove and are meant to be illustrative and are not limiting:</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">AlaAsnLysIleSerTyrGln|SerSerSerThrGlu-amide       (SEQ.ID.NO.: 11)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">Ac-AlaAsnLysIleSerTyrGln|SerSerSerThrLeu          (SEQ.ID.NO.: 70)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">Ac-AlaAsnLysIleSerTyrGln|SerSerSerThrGlu-amide    (SEQ.ID.NO.: 11)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">Ac-AlaAsnLysIleSerTyrGln|SerSerSerThrLeu-amide    (SEQ.ID.NO.: 70)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">Ac-AlaAsnLysIleSerTyrGln|SerAlaSerThrGlu-amide    (SEQ.ID.NO.: 73)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">Ac-AlaAsnLysIleSerTyrGln|SerSerLysThrGlu-amide    (SEQ.ID.NO.: 74)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">Ac-AlaAsnLysIleSerTyrGln|SerSerThrGlu-amide       (SEQ.ID.NO.: 75)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">Ac-AlaAsnLysIleSerTyrGln|SerSerGlnThrGlu-amide    (SEQ.ID.NO.: 78)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">Ac-AlaAsnLysIleSerTyrGln|SerAlaLysThrGlu-amide    (SEQ.ID.NO.:79)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">Ac-AlaAsnLysIleSerTyrGln|SerThrGlu-amide          (SEQ.ID.NO.: 81)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">Ac-AlaAsnLysSerTyrGln|SerSerThrGlu-amide          (SEQ.ID.NO.: 82)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">Ac-AlaAsnLysAlaSerTyrGln|SerAlaSerThrGlu-amide    (SEQ.ID.NO.: 84)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">Ac-AlaAsnGluIleSerTyrGln|SerAlaSerThrGlu-amide    (SEQ.ID.NO.: 85)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">Ac-AsnLysIleSerTyrGln|SerSer-amide                (SEQ.ID.NO.: 16)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">Ac-LysIleSerTyrGln|SerSer-amide                   (SEQ.ID.NO.: 86)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">Ac-SerTyrGlnSerSerThrGlu-amide                             (SEQ.ID.NO.: 87)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">Ac-AlaSerTyrGln|SerSerThrGlu-amide                (SEQ.ID.NO.: 89)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">Ac-AlaAsnLysIleSerTyrTyr|SerSerSerThrGlu-amide    (SEQ.ID.NO.: 92)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">Ac-AlaAsnLysIleSerTyrTyr|SerAlaSerThrGlu-amide    (SEQ.ID.NO.: 93)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">Ac-AlaSerTyrGln|SerSerLeu-amide                   (SEQ.ID.NO.: 94)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">Ac-AlaAsnSerTyrGln|SerSerSerThrGlu-amide          (SEQ.ID.NO.: 95)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">Ac-AlaSerTyrGln|SerSerSerThrGlu-amide             (SEQ.ID.NO.: 96)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">Ac-SerTyrGln|SerSerSerThrGlu-amide                (SEQ.ID.NO.: 97)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">Ac-AlaAsnLysAlaSerTyrGln|SerAlaSerCys-amide       (SEQ.ID.NO.: 98)</pre>
    
    <p>A person of ordinary skill in the peptide chemistry art would readily appreciate that certain amino acids in a biologically active oligopeptide may be replaced by other homologous, isosteric and/or isoelectronic amino acids wherein the biological activity of the original oligopeptide has been conserved in the modified oligopeptide. The following list of amino acid replacements is meant to be illustrative and is not limiting:</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">______________________________________ OriginalAmino Acid            Replacement Amino Acid(s)______________________________________Ala                        Gly  Arg                  Lys, Ornithine  Asn                  Gln  Asp                  Glu  Glu                  Asp  Gln                  Asn  Gly                  Ala  Ile                  Val, Leu, Met, Nle  Leu                  Ile, Val, Met, Nle  Lys                Arg, Ornithine  Met                Leu, Ile, Nle, Val  Ornithine          Lys, Arg  Phe                Tyr, Ttp  Ser                Thr  Thr                Ser  Trp                Phe, Tyr  Tyr                Phe,Trp  Val                Leu, Ile, Met, Nle______________________________________</pre>
    
    <p>Thus, for example, the following oligopeptides may be synthesized by techniques well known to persons of ordinary skill in the art and would be expected to be proteolytically cleaved by free PSA:</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">AsnArgIleSerTyrGln|Ser                            (SEQ.ID.NO.: 21)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">AsnLysValSerTyrGln|Ser                            (SEQ.ID.NO.: 22)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">AsnLysMetSerTyrGln|SerSer                         (SEQ.ID.NO.: 23)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">AsnLysLeuSerTyrGln|SerSer                         (SEQ.ID.NO.: 24)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">AsnLysIleThrTyrGln|SerSerSer                      (SEQ.ID.NO.: 25)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">AsnLysIleSerPheGln|SerSerSer                      (SEQ.ID.NO.: 26)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">AsnLysIleSerTrpGln|SerSerSerThr                   (SEQ.ID.NO.: 27)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">AsnLysIleSerTyrAsn|SerSerSerThr                   (SEQ.ID.NO.: 28)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">AsnLysIleSerTyrGln|ThrSerSerThr                   (SEQ.ID.NO.: 29)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">AsnLysIleSerTyrGln|Ser                            (SEQ.ID.NO.: 30)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlnLysIleSerTyrGln|SerSer                         (SEQ.ID.NO.: 31)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">AsnArgIleThrTyrGln|SerSerSer                      (SEQ.ID.NO.: 32)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">AsnArgIleSerPheGln|SerSerSerThr                   (SEQ.ID.NO.: 33)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">AsnArgIleSerTrpGln|SerSerSerThr                   (SEQ.ID.NO.: 35)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">AsnArgIleSerTyrGln|ThrSerSerThr                   (SEQ.ID.NO.: 36)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">AsnLysIleThrTyrGln|ThrSerSerThr                   (SEQ.ID.NO.: 37)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">AsnLysLeuSerTyrGln|ThrSerSerThr                   (SEQ.ID.NO.: 38)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlnLysLeuSerTyrGln|SerSerSerThr                   (SEQ.ID.NO.: 39)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">AsnArgLeuSerTyrGln|ThrSerSerThr                   (SEQ.ID.NO.: 40)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">AsnLysValSerPheGln|SerSerSerThr                   (SEQ.ID.NO.: 41)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">AsnArgValSerTrpGln|SerSerSerThr                   (SEQ.ID.NO.: 42)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlnLysValSerTyrGln|SerSerSerThr                   (SEQ.ID.NO.: 43)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlnLysIleSerTyrGln|ThrSerSerThr                   (SEQ.ID.NO.: 34)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">AsnLysIleSerTyrGln|SerSerSerThr                   (SEQ.ID.NO.: 44)</pre>
    
    <p>Similarly, the following oligopeptides may be synthesized by techniques well known to persons of ordinary skill in the art and would be expected to be proteolytically cleaved by free PSA:</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlyGluGlnGlyValGlnLysAspValSerGlnSerSerIleTyr|SerGlnThrGlu, (SEQ.ID.NO.: 45)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlyGluAsnGlyLeuGlnLysAspValSerGlnSerSerIleTyr|SerGlnThrGlu, (SEQ.ID.NO.: 47)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlyGluAsnGlyValAsnLysAspValSerGlnSerSerIleTyr|SerGlnThrGlu, (SEQ.ID.NO.: 48)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlyGluAsnGlyValGlnArgAspValSerGlnArgSerIleTyr|SerGlnThrGlu, (SEQ.ID.NO.: 49)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlyGluAsnGlyValGlnLysAspValSerGlnLysSerIleTyr|SerGlnThrGlu, (SEQ.ID.NO.: 50)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlyGluAsnGlyValGlnLysAspLeuSerGlnThrSerIleTyr|SerGlnThrGlu, (SEQ.ID.NO.: 51)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlyGluAsnGlyValGlnLysAspValSerGlnSerSerIlePhe|SerGlnThrGlu, (SEQ.ID.NO.: 52)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlyGluAsnGlyValGlnLysAspMetSerGlnSerSerIleTyr|ThrGlnThrGlu, (SEQ.ID.NO.: 53)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlyGluAsnGlyValGlnLysAspValSerGlnArgSerIleTyr|ThrGlnThrGlu, (SEQ.ID.NO.: 54)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlyGluAsnGlyValGlnLysAspValSerGlnSerSerIleTyr|SerGlnSerGlu, (SEQ.ID.NO.: 55)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlyGluAsnGlyValGlnLysAspValSerGlnArgSerIleTyr|SerAsnThrGlu, (SEQ.ID.NO.: 56)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlyLysAlaIleSerSerGlnTyr|SerAsnThrGluGluArgLeu,   (SEQ.ID.NO.: 57)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlyArgGlyIleSerSerGlnTyr|SerAsnThrGluGluArgLeu,   (SEQ.ID.NO.: 59)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlyLysGlyIleThrSerGlnTyr|SerAsnThrGluGluArgLeu,   (SEQ.ID.NO.: 60)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlyLysGlyIleSerThrGlnTyr|SerAsnThrGluGluArgLeu,   (SEQ.ID.NO.: 61)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlyLysGlyIleSerSerAsnTyr|SerAsnThrGluGluArgLeu,   (SEQ.ID.NO.: 62)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">AlaLysGlyIleSerSerGlnTyr|SerAsnThrGluGluArgLeu,   (SEQ.ID.NO.: 63)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlyLysGlyIleSerSerGlnPhe|SerAsnThrGluGluArgLeu,   (SEQ.ID.NO.: 64)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlyLysGlyIleSerSerGlnTyr|ThrAsnThrGluGluArgLeu,   (SEQ.ID.NO.: 65)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlyLysGlyIleSerSerGlnTyr|SerAsnSerGluGluArgLeu, and (SEQ.ID.NO.: 58)</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="equation">GlyLysGlyIleSerSerGlnTyr|SerAsnThrAspGluArgLeu;   (SEQ.ID.NO.: 46)</pre>
    
    <p>and the like.</p>
    <p>The inclusion of the symbol "|" within an amino acid sequence indicates the point within that sequence where the oligopeptide is proteolytically cleaved by free PSA.</p>
    <p>The invention also concerns a method for assaying proteolytic free PSA activity in a composition. This is an important aspect of the invention in that such an assay system provides one with the ability to measure quantitatively the amount of free PSA present in certain physiological fluids and tissues. Such an assay will also provide not only the ability to follow isolation and purification of free PSA, but also is a basis for a screening assay for inhibitors of the proteolytic activity of free PSA. The assay method generally includes simply determining the ability of a composition suspected of containing enzymatically active free PSA to proteolytically cleave the oligopeptide.</p>
    <p>Typically, the assay protocol is carried out using one of the oligopeptides described hereinabove. However, one may find a particular benefit in construction of an assay wherein the oligopeptide containing the cleavage site is labeled so that one can measure the appearance of such a label, for example, a radioactive label, in both the uncleaved oligopeptide and the portion of the oligopeptide remaining after cleavage which contains the label.</p>
    <p>The instant invention further relates to a method for identifying compounds (hereinafter referred to as candidate compounds) that will inhibit the proteolytic activity of free PSA. It is contemplated that this screening technique will prove useful in the general identification of any candidate compound that will serve such as an inhibitory purpose, whether or not the candidate compound is proteinaceous or peptidyl in structure.</p>
    <p>Thus, the present invention is also directed to a method for determining the ability of a test substance to inhibit the proteolytic activity of free PSA, the method which comprises:</p>
    <p>(a) reacting a substrate, wherein the substrate comprises a sequence of amino acids that is recognized and selectively proteolytically cleaved by free prostate specific antigen, with free prostate specific antigen in the presence of a test substance; and</p>
    <p>(b) detecting whether the substrate has been cleaved, in which the ability of the test substance to inhibit proteolytic activity of prostate specific antigen is indicated by a decrease in the cleavage of the substrate as compared to the cleavage of the substrate in the absence of the test substance.</p>
    <p>The candidate screening assay is quite simple to set up and perform, and is related in many ways to the assay discussed above for determining proteolytic activity. Thus, after obtaining a relatively purified preparation of free PSA, one will desire to simply admix a test substance with the proteolytic preparation, preferably under conditions which would allow the PSA to perform its cleavage function but for inclusion of a inhibitory substance. Thus, for example, one will typically desire to include within the admixture an amount of a known oligopeptide having a PSA specific cleavage site, such as those oligopeptides described hereinabove. In this fashion, one can measure the ability of the test substance to reduce cleavage of the oligopeptide relatively in the presence of the test substance.</p>
    <p>Accordingly, one will desire to measure or otherwise determine the activity of the free PSA in the absence of the added test substance relative to the activity in the presence of the test substance in order to assess the relative inhibitory capability of the test substance.</p>
    <p>The instant invention also relates to novel anti-cancer compositions useful for the treatment of prostate cancer. Such compositions comprise the oligopeptides of the instant invention covalently bonded directly, or through a chemical linker, to a cytotoxic agent. Such a combination of an oligopeptide and cytotoxic agent may be termed a conjugate. Ideally, the cytotoxic activity of the cytotoxic agent is greatly reduced or absent when the oligopeptide containing the PSA proteolytic cleavage site is bonded directly, or through a chemical linker, to the cytotoxic agent and is intact. Also ideally, the cytotoxic activity of the cytotoxic agent increases significantly or returns to the activity of the unmodified cytotoxic agent upon proteolytic cleavage of the attached oligopeptide at the cleavage site. While it is not necessary for practicing this aspect of the invention, the most preferred embodiment of this aspect of the invention is a conjugate wherein the oligopeptide, and the chemical linker if present, are detached from the cytotoxic agent by the proteolytic activity of the free PSA and any other native proteolytic enzymes present in the tissue proximity, thereby releasing unmodified cytotoxic agent into the physiological environment at the place of proteolytic cleavage.</p>
    <p>It is understood that the oligopeptide of the instant invention that is conjugated to the cytotoxic agent, whether through a direct covalent bond or through a chemical linker, does not need to be the oligopeptide that has the greatest recognition by free PSA and is most readily proteolytically cleaved by free PSA. Thus, the oligopeptide that is selected for incorporation in such an anti-cancer composition will be chosen both for its selective, proteolytic cleavage by free PSA and for the cytotoxic activity of the cytotoxic agent-proteolytic residue conjugate (or, in what is felt to be an ideal situation, the unmodified cytotoxic agent) which results from such a cleavage.</p>
    <p>Because the conjugates of the invention can be used for modifying a given biological response, cytotoxic agent is not to be construed as limited to classical chemical therapeutic agents. For example, the cytotoxic agent may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor, Œ±-interferon, Œ≤-interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.</p>
    <p>The preferred cytotoxic agents include, in general, alkylating agents, antiproliferative agents, tubulin binding agents and the like. Preferred classes of cytotoxic agents include, for example, the anthracycline family of drugs, the vinca drugs, the mitomycins, the bleomycins, the cytotoxic nucleosides, the pteridine family of drugs, diynenes, and the podophyllotoxins. Particularly useful members of those classes include, for example, doxorubicin, carminomycin, daunorubicin, aminopterin, methotrexate, methopterin, dichloromethotrexate, mitomycin C, porfiromycin, 5-fluorouracil, 6-mercaptopurine, cytosine arabinoside, podophyllotoxin, or podophyllotoxin derivatives such as etoposide or etoposide phosphate, melphalan, vinblastine, vincristine, leurosidine, vindesine, leurosine and the like. Other useful cytotoxic agents include estramustine, cisplatin and cyclophosphamide. One skilled in the art may make chemical modifications to the desired compound in order to make reactions of that compound more convenient for purposes of preparing conjugates of the invention.</p>
    <p>A highly preferred group of cytotoxic agents for the present invention include drugs of the following formulae:</p>
    <heading>THE METHOTREXATE GROUP OF FORMULA (1) ##STR1## in which R<sup>12</sup> is amino or hydroxy;</heading> <p>R<sup>7</sup> is hydrogen or methyl;</p>
    <p>R<sup>8</sup> is hydrogen, fluoro, chloro, bromo or iodo;</p>
    <p>R<sup>9</sup> is hydroxy or a moiety which completes a salt of the carboxylic acid;</p>
    <heading>THE MITOMYCIN GROUP OF FORMULA (2) ##STR2## in which R<sup>10</sup> is hydrogen or methyl;</heading> <heading>THE BLEOMYCIN GROUP OF FORMULA (3) ##STR3## in which R<sup>11</sup> is hydroxy, amino, C<sub>1</sub> -C<sub>3</sub> alkylamino, di(C<sub>1</sub> -C<sub>3</sub> alkyl)amino, C<sub>4</sub> -C<sub>6</sub> polymethylene amino, ##STR4##</heading> <heading>MELPHALAN OF FORMULA (4) ##STR5##</heading> <heading>6-MERCAPTOPURINE OF FORMULA (5) ##STR6##</heading> <heading>A CYTOSINE ARABINOSIDE OF FORMULA (6) ##STR7##</heading> <heading>THE PODOPHYLLOTOXINS OF FORMULA (7) ##STR8## in which R<sup>13</sup> is hydrogen or methyl;</heading> <p>R<sup>14</sup> is methyl or thienyl;</p>
    <p>or a phosphate salt thereof;</p>
    <heading>THE VINCA ALKALOID GROUP OF DRUGS OF FORMULA (8) ##STR9## in which R<sup>15</sup> is H, CH<sub>3</sub> or CHO; when R<sup>17</sup> and R<sup>18</sup> are taken singly;</heading> <p>R<sup>18</sup> is H, and one of R<sup>16</sup> and R<sup>17</sup> is ethyl and the other is H or OH; when R<sup>17</sup> and R<sup>18</sup> are taken together with the carbons to which they are attached, they form an oxirane ring in which case R<sup>16</sup> is ethyl;</p>
    <p>R<sup>19</sup> is hydrogen, (C<sub>1</sub> -C<sub>3</sub> alkyl)-CO, or chlorosubstituted (C<sub>1</sub> -C<sub>3</sub> alkyl)-CO;</p>
    <heading>DIFLUORONUCLEOSIDES OF FORMULA (9) ##STR10## in which R<sup>21</sup> is a base of one of the formulae: ##STR11## in which R<sup>22</sup> is hydrogen, methyl, bromo, fluoro, chloro or iodo;</heading> <p>R<sup>23</sup> is --OH or --NH<sub>2</sub> ;</p>
    <p>R<sup>24</sup> is hydrogen, bromo, chloro or iodo; or,</p>
    <heading>THE ANTHRACYCLINES ANTIBIOTICS OF FORMULA (10) ##STR12## wherein R<sup>1</sup> is --CH<sub>3</sub>, --CH<sub>2</sub> OH, --CH<sub>2</sub> OCO(CH<sub>2</sub>)<sub>3</sub> CH<sub>3</sub>, or --CH<sub>2</sub> OCOCH(OC<sub>2</sub> H<sub>5</sub>)<sub>2</sub> ;</heading> <p>R<sup>3</sup> is --OCH<sub>3</sub>, --OH or --H;</p>
    <p>R<sup>4</sup> is --NH<sub>2</sub>, --NHCOCF<sub>3</sub>, 4-morpholinyl, 3-cyano-4-morpholinyl, 1-piperidinyl, 4-methoxy-1-piperidinyl, benzylamine, dibenzylamine, cyanomethylamine, or 1-cyano-2-methoxyethyl amine;</p>
    <p>R<sup>5</sup> is --OH --OTHP or --H; and</p>
    <p>R<sup>6</sup> is --OH or --H provided that R<sup>6</sup> is not --OH when R<sup>5</sup> is --OH or --OTHP.</p>
    <heading>ESTRAMUSTINE (11) ##STR13##</heading> <heading>CYCLOPHOSPHAMIDE (12) ##STR14##</heading> <p>The most highly preferred drugs are the anthracycline antiobiotic agents of Formula (10), described previously. One skilled in the art understands that this structural formula includes compounds which are drugs, or are derivatives of drugs, which have acquired in the art different generic or trivial names. Table 1, which follows, represents a number of anthracycline drugs and their generic or trivial names and which are especially preferred for use in the present invention.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">                                  TABLE 1__________________________________________________________________________                                    (11)                              ##STR15##   - Compound  R<sub>1</sub>    R<sub>3</sub>                 R<sub>4</sub>                        R<sub>5</sub>                            R<sub>6</sub>__________________________________________________________________________daunorubicin<sup>a</sup>  CH<sub>3</sub>   OCH<sub>3</sub>                 NH<sub>2</sub>                        OH  4H  doxorubicin<sup>b</sup>        CH<sub>2</sub> OH           OCH<sub>3</sub>    NH<sub>2</sub>                            OH       H  detorubicin         CH<sub>2</sub> OCOCH(OC<sub>2</sub> H<sub>5</sub>)<sub>2</sub>   OCH<sub>3</sub>                              NH<sub>2</sub>    OH       H  carminomycin        CH<sub>3</sub>             OH      NH<sub>2</sub>    OH       H  idarubicin          CH<sub>3</sub>             H       NH<sub>2</sub>    OH       H  epirubicin          CH<sub>2</sub> OH           OCH<sub>3</sub>    NH<sub>2</sub>    OH                                OH  esorubicin          CH<sub>2</sub> OH           OCH<sub>3</sub>    NH<sub>2</sub>                                 H  THP                 CH<sub>2</sub> OH           OCH<sub>3</sub>    NH<sub>2</sub>    OTHP                                H  AD-32               CH<sub>2</sub> OCO(CH<sub>2</sub>)<sub>3</sub> CH<sub>3</sub> OCH<sub>3</sub>                            NHCOCF<sub>3</sub>  OH       H__________________________________________________________________________ <sup>a</sup> "daunomycin" is an alternative name for daunorubicin <sup>b</sup> "adriamycin"  is an alternative name for doxorubicin</pre>
    
    <p>Of the compounds shown in Table 1, the most highly preferred drug is doxorubicin. Doxorubicin (also referred to herein as "DOX") is that anthracycline of Formula (10) in which R<sub>1</sub> is --CH<sub>2</sub> OH, R<sub>3</sub> is --OCH<sub>3</sub>, R<sub>4</sub> is --NH<sub>2</sub>, R<sub>5</sub> is --OH, and R<sub>6</sub> is --H.</p>
    <p>The oligopeptides, peptide subunits and peptide derivatives (also termed "peptides") of the present invention can be synthesized from their constituent amino acids by conventional peptide synthesis techniques, preferably by solid-phase technology. The peptides are then purified by reverse-phase high performance liquid chromatography (HPLC).</p>
    <p>Standard methods of peptide synthesis are disclosed, for example, in the following works: Schroeder et al., "The Peptides", Vol. I, Academic Press 1965; Bodansky et al., "Peptide Synthesis", Interscience Publishers, 1966; McOmie (ed.) "Protective Groups in Organic Chemistry", Plenum Press, 1973; Barany et al., "The Peptides: Analysis, Synthesis, Biology" 2, Chapter 1, Academic Press, 1980, and Stewart et al., "Solid Phase Peptide Synthesis", Second Edition, Pierce Chemical Company, 1984. The teachings of these works are hereby incorporated by reference.</p>
    <p>The conjugates of the instant invention which comprise the oligopeptide containing the PSA cleavage site and a cytotoxic agent may similarly be synthesized by techniques well known in the medicinal chemistry art. For example, a free amine moiety on the cytotoxic agent may be covalently attached to the oligopeptide at the carboxyl terminus such that an amide bond is formed. Similarly, an amide bond may be formed by covalently coupling an amine moiety of the oligopeptide and a carboxyl moiety of the cytotoxic agent. For these purposes a reagent such as a combination of 2-(1H-benzotriazol-1-yl)-1,3,3-tetramethyluronium hexafluorophosphate (known as HBTU) and 1-hyroxybenzotriazole hydrate known as HOBT), dicyclohexylcarbodiimide (DCC), N-ethyl-N-(3-dimethylaminopropyl)-carbodiimide (EDC), diphenylphosphorylazide (DPPA), benzotriazol-1-yl-oxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP) and the like may be utilized.</p>
    <p>Furthermore, the instant conjugate may be formed by a non-peptidyl bond between the PSA cleavage site and a cytotoxic agent. For example, the cytotoxic agent may be covalently attached to the carboxyl terminus of the oligopeptide via a hydroxyl moiety on the cytotoxic agent, thereby forming an ester linkage. For this purpose a reagent such as a combination of HBTU and HOBT, a combination of BOP and imidazole, a combination of DCC and DMAP, and the like may be utilized. The carboxylic acid may also be activated by forming the nitrophenyl ester or the like and reacted in the presence of DBU (1,8-diazabicyclo[5,4,0]undec-7-ene.</p>
    <p>The instant conjugate may also be formed by attachment of the oligopeptide to the cytotoxic agent via a linker unit. Such linker units include, for example, a biscarbonyl alkyl diradical whereby an amine moiety on the cytotoxic agent is connected with the linker unit to form an amide bond and the amino terminus of the oligopeptide is connected with the other end of the linker unit also forming an amide bond. Other such linker units which are stable to the physiological environment when not in the presence of free PSA, but are cleavable upon the cleavage of the PSA proteolytic cleavage site, are also envisioned. Furthermore, linker units may be utilized that, upon cleavage of the PSA proteolytic cleavage site, remain attached to the cytotoxic agent but do not significantly decrease the cytotoxic activity of such a post-cleavage cytotoxic agent derivative when compared with an unmodified cytotoxic agent.</p>
    <p>One skilled in the art understands that in the synthesis of compounds of the invention, one may need to protect or block various reactive functionalities on the starting compounds and intermediates while a desired reaction is carried out on other portions of the molecule. After the desired reactions are complete, or at any desired time, normally such protecting groups will be removed by, for example, hydrolytic or hydrogenolytic means. Such protection and deprotection steps are conventional in organic chemistry. One skilled in the art is referred to Protective Groups in Organic Chemistry, McOmie, ed., Plenum Press, NY, N.Y. (1973); and, Protective Groups in Organic Synthesis, Greene, ed., John Wiley &amp; Sons, NY, N.Y. (1981) for the teaching of protective groups which may be useful in the preparation of compounds of the present invention.</p>
    <p>By way of example only, useful amino-protecting groups may include, for example, C<sub>1</sub> -C<sub>10</sub> alkanoyl groups such as formyl, acetyl, dichloroacetyl, propionyl, hexanoyl, 3,3-diethylhexanoyl, Œ≥-chlorobutryl, and the like; C<sub>1</sub> -C<sub>10</sub> alkoxycarbonyl and C<sub>5</sub> -C<sub>15</sub> aryloxycarbonyl groups such as tert-butoxycarbonyl, benzyloxycarbonyl, allyloxycarbonyl, 4-nitrobenzyloxycarbonyl, fluorenylmethyloxycarbonyl and cinnamoyloxycarbonyl; halo-(C<sub>1</sub> -C<sub>10</sub>)-alkoxycarbonyl such as 2,2,2-trichloroethoxycarbonyl; and C<sub>1</sub> -C<sub>15</sub> arylalkyl and alkenyl group such as benzyl, phenethyl, allyl, trityl, and the like. Other commonly used amino-protecting groups are those in the form of enamines prepared with Œ≤-keto-esters such as methyl or ethyl acetoacetate.</p>
    <p>Useful carboxy-protecting groups may include, for example, C<sub>1</sub> -C<sub>10</sub> alkyl groups such as methyl, tert-butyl, decyl; halo-C<sub>1</sub> -C<sub>10</sub> alkyl such as 2,2,2-trichloroethyl, and 2-iodoethyl; C<sub>5</sub> -C<sub>15</sub> arylalkyl such as benzyl, 4-methoxybenzyl, 4-nitrobenzyl, triphenylmethyl, diphenylmethyl; C<sub>1</sub> -C<sub>10</sub> alkanoyloxymethyl such as acetoxymethyl, propionoxymethyl and the like; and groups such as phenacyl, 4-halophenacyl, allyl, dimethylallyl, tri-(C<sub>1</sub> -C<sub>3</sub> alkyl)silyl, such as trimethylsilyl, Œ≤-p-toluenesulfonylethyl, Œ≤-p-nitrophenyl-thioethyl, 2,4,6-trimethylbenzyl, Œ≤-methylthioethyl, phthalimidomethyl, 2,4-dinitrophenylsulphenyl, 2-nitrobenzhydryl and related groups.</p>
    <p>Similarly, useful hydroxy protecting groups may include, for example, the formyl group, the chloroacetyl group, the benzyl group, the benzhydryl group, the trityl group, the 4-nitrobenzyl group, the trimethylsilyl group, the phenacyl group, the tert-butyl group, the methoxymethyl group, the tetrahydropyranyl group, and the like.</p>
    <p>With respect to the preferred embodiment of an oligopeptide combined with the anthracycline antibiotic doxorubicin, the following Reaction Schemes illustrate the synthsis of the conjugates of the instant invention. ##STR16##</p>
    <p>Reaction Scheme VI illustrates preparation of conjugates of the oligopeptides of the instant invention and the vinca alkaloid cytotoxic agent vinblastine. Attachement of the N-terminus of the oligopeptide to vinblastine is illustrated (S. P. Kandukuri et al. J. Med. Chem. 28:1079-1088 (1985)). However, conjugation of the oligopeptide at other positions and functional groups of vinblastine and at the C-terminus of the oligopeptide is also expected to provide compounds useful in the treatment of prostate cancer.</p>
    <p>It is also understood that conjugates may be prepared wherein the N-terminus of the oligopeptide of the instant invention is covalently attached to one cytotoxic agent, such as vinblastine, while the C-terminus is simultaneously attached to another cytotoxic agent, which is the same or different cytotoxic agent, such as doxorubicin. Such a polycytotoxic conjugate may offer advantages over a conjugate containing only one cytotoxic agent. ##STR17##</p>
    <p>The oligopeptide-cytotoxic agent conjugate of the instant invention wherein the cytotoxic agent is the preferred cytotoxic agent doxorubicin may be described by the general formula I below: ##STR18## wherein: oligopeptide is an oligopeptide which is specifically recognized by the free prostate specific antigen (PSA) and is capable of being proteolytically cleaved by the enzymatic activity of the free prostate specific antigen;</p>
    <p>X<sub>L</sub> is absent or is an amino acid selected from:</p>
    <p>a) phenylalanine,</p>
    <p>b) leucine,</p>
    <p>c) valine,</p>
    <p>d) isoleucine,</p>
    <p>e) (2-naphthyl)alanine,</p>
    <p>f) cyclohexylalanine,</p>
    <p>g) diphenylalanine,</p>
    <p>h) norvaline, and</p>
    <p>j) norleucine;</p>
    <p>R is hydrogen or --(C‚ïêO)R<sup>1</sup> ; and</p>
    <p>R<sup>1</sup> is C<sub>1</sub> -C<sub>6</sub> -alkyl or aryl.</p>
    <p>In a preferred embodiment of the oligopeptide-cytotoxic agent conjugate:</p>
    <p>oligopeptide is an oligomer that comprises an amino acid sequence selected from:</p>
    <p>a) AsnLysIleSerTyrGln|Ser (SEQ.ID.NO.: 13),</p>
    <p>b) LysIleSerTyrGln|Ser (SEQ.ID.NO.: 14),</p>
    <p>c) GlyGluAsnGlyValGlnLysAspValSerGlnXaaSerIleTyr|SerGlnThrGlu (SEQ.ID.NO.: 15),</p>
    <p>d) GlyLysGlyIleSerSerGlnTyr|SerAsnThrGluGluArgLeu (SEQ.ID.NO.: 2),</p>
    <p>e) AsnLysIleSerTyrTyr|Ser (SEQ.ID.NO.: 127),</p>
    <p>f) AsnLysAlaSerTyrGln|Ser (SEQ.ID.NO.: 128),</p>
    <p>g) SerTyrGln|SerSer (SEQ.ID.NO.: 129), and</p>
    <p>h) hArgTyrGln|SerSer (SEQ.ID.NO.: 141);</p>
    <p>wherein Xaa is any natural amino acid;</p>
    <p>X<sub>L</sub> is absent or is an amino acid selected from:</p>
    <p>a) leucine,</p>
    <p>b) isoleucine,</p>
    <p>c) norleucine, and</p>
    <p>d) valine; and</p>
    <p>R is acetyl, pivaloyl or benzoyl.</p>
    <p>The following compounds are specific examples of the oligopeptide-cytotoxic agent conjugate of the instant invention: ##STR19## wherein X is: ##STR20##</p>
    <p>It is well known in the art, and understood in the instant invention, that peptidyl therapeutic agents such as the instant oligopeptide-cytotoxic agent conjugates preferably have the terminal amino moiety of any oligopeptide substituent protected with a suitable protecting group, such as acetyl, benzoyl, pivaloyl and the like. Such protection of the terminal amino group reduces or eliminates the enzymatic degradation of such peptidyl therapeutic agents by the action of exogenous amino peptidases which are present in the blood plasma of warm blooded animals.</p>
    <p>The oligopeptide-cytotoxic agent conjugates of the invention are administered to the patient in the form of a pharmaceutical composition which comprises a conjugate of Formula (I) and a pharmaceutically acceptable carrier, excipient or diluent therefor. As used, "pharmaceutically acceptable" refers to those agents which are useful in the treatment or diagnosis of a warm-blooded animal including, for example, a human, equine, procine, bovine, murine, canine, feline, or other mammal, as well as an avian or other warm-blooded animal. The preferred mode of administration is parenterally, particularly by the intravenous, intramuscular, subcutaneous, intraperitoneal, or intralymphatic route. Such formulations can be prepared using carriers, diluents or excipients familiar to one skilled in the art. In this regard, See, e.g. Remington's Pharmaceutical Sciences, 16th ed., 1980, Mack Publishing Company, edited by Osol et al. Such compositions may include proteins, such as serum proteins, for example, human serum albumin, buffers or buffering substances such as phosphates, other salts, or electrolytes, and the like. Suitable diluents may include, for example, sterile water, isotonic saline, dilute aqueous dextrose, a polyhydric alcohol or mixtures of such alcohols, for example, glycerin, propylene glycol, polyethylene glycol and the like. The compositions may contain preservatives such as phenethyl alcohol, methyl and propyl parabens, thimerosal, and the like. If desired, the composition can include about 0.05 to about 0.20 percent by weight of an antioxidant such as sodium metabisulfite or sodium bisulfite.</p>
    <p>For intravenous administration, the composition preferably will be prepared so that the amount administered to the patient will be from about 0.01 to about 1 g of the conjugate. Preferably, the amount administered will be in the range of about 0.2 g to about 1 g of the conjugate. The conjugates of the invention are effective over a wide dosage range depending on factors such as the disease state to be treated or the biological effect to be modified, the manner in which the conjugate is administered, the age, weight and condition of the patient as well as other factors to be determined by the treating physician. Thus, the amount administered to any given patient must be determined on an individual basis.</p>
    <p>One skilled in the art will appreciate that although specific reagents and reaction conditions are outlined in the following examples, modification can be made which are meant to be encompassed by the spirit and scope of the invention. The following preparations and examples, therefore, are provided to further illustrate the invention, and are not limiting.</p>
    <heading>EXAMPLES</heading> <heading>EXAMPLE 1</heading> <heading>Identification of the Semenogelin PSA Mediated Cleavage Site</heading> <p>Liquefaction of the seminal gel parallels proteolytic fragmentation of semenogelin I [Lilja, H., Laurell, C. B., (1984) Scand. J. Clin. Lab. Inves. 44, 447-452]. It is believed that the proteolytic fragmentation of semenogelin is mainly due to the proteolytic activity of prostate-specific antigen [Lilja, H., (1985) J. Clin. Invest. 76, 1899-1903]. Utilizing the published sequence of semenogelin I [Lilja, H., Abrahamsson, P. A., Lundwall, A., (1989) J. of Biol. Chem. 264, 1894-1900] (FIG. 1) we designed polymerase chain reaction primers to clone the semenogelin cDNA from a commercially available prostatic cDNA library (Clonetech, Palo Alto, Calif.). The purified semenogelin cDNA was placed into the bacterial expression vector pTAC [Linemeyer, D. L., Kelly, L. J., Minke, J. G., Gimenez-Gallego, G., DeSalvo, J. and Thomas, K. A., (1987) Bio/Technology 5, 960-965]. The semenogelin cDNA was designed so that a tubulin epitope was placed at the carboxyl end of semenogelin protein. The bacterially expressed semenogelin protein was purified on an anti-tubulin antibody column. The purified semenogelin I protein was mixed with commercially prepared prostate-specific antigen (PSA) (York Biologicals International, Stony Brook, N.Y.) in an 100 to 1 molar ratio (semenogelin I/PSA) in 12 mM Tris pH 8.0, 25 mM NaCl, 0.5 mM CaCl<sub>2</sub>, and incubated for various times. The digest was fractionated by polyacrylamide gel electrophoresis and transferred by electrophoresis to ProBlott filter paper (Applied Biosystems, Inc., Foster City, Calif.) in CAPS buffer [Matsudaira, P., (1987) J. Biol. Chem. 252, 10035-10038]. The ProBlott filter paper was stained with coomassie blue to identify the novel PSA generated semenogelin I protein fragments. The novel fragments were cut out of the filter with a scalpel and submitted for sequence determination. After the proteolytic fragments were identified by variable time digestion, a 10 minute digestion reaction was performed. The affinity of PSA for the 5 potential cleavage sites in semenogelin I was determined to be as follows: site 349/350&gt;site 375/376&gt;site 289/290=site 315/316&gt;site 159/160. The relative affinities were derived from the comassie blue staining intensity of each PSA generated peptide fragment. These intensities had approximate ratios of 3:1:0.6:0.3.</p>
    <heading>EXAMPLE 2</heading> <heading>Preparation of Oligopeptides which Comprise the PSA Mediated Cleavage Site</heading> <p>Oligopeptides were prepared by solid-phase synthesis, using a double coupling protocol for the introduction of amino acids on the Applied Biosystems model 430A automated peptide synthesizer. Deprotection and removal of the oligopeptide from the resin support were achieved by treatment with liquid hydrofluoric acid. The oligopeptides were purified by preparative high pressure liquid chromatography on reverse phase C18 silica columns using an aqueous 0.1 % trifluoroacetic acid/acetonitrile gradient. Identity and homogeneity of the oligopeptides were confirmed by amino acid composition analysis, high pressure liquid chromatography, and fast atom bombardment mass spectral analysis. The oligopeptides that were prepared by this method are shown in FIG. 2.</p>
    <heading>EXAMPLE 3</heading> <heading>Assessment of the Recognition of Oligopeptides by Free PSA</heading> <p>The oligopeptides prepared as described in Example 2 were individually dissolved in PSA digestion buffer (12 mM tris(hydroxymethyl)aminomethane pH8.0, 25 mM NaCl, 0.5 mM CaCl<sub>2</sub>) and the solution added to PSA at a molar ration of 100 to 1. The reaction is quenched after various reaction times by the addition of trifluoroacetic acid (TFA) to a final 1% (volume/volume). The quenched reaction was analyzed by HPLC on a reversed-phase C18 column using an aqueous 0.1% TFA/acetonitrile gradient. The results of the assessment are shown in FIG. 2. Other oligopeptides prepared as described in Example 2 were tested in the same assay wherein the reaction was quenched at 4 hours. Those results of the assessment are shown in FIG. 3. The removal of an asparagine residue from the amino terminus of the oligopeptide results in a significant loss of PSA mediated peptide hydrolysis, while the presence of a glutamic acid residue at the carboxyl end of the peptide appears not to be essential to recognition by PSA.</p>
    <heading>EXAMPLE 4</heading> <heading>Preparation of Non-cleavable Oligopeptide-Doxorubicin Conjugates</heading> <p>The derivatives of doxorubicin shown in Table 2 were prepared using the following general reaction: To a mixture of doxorubicin (Sigma) and the corresponding peptide (prepared by solid phase synthesis or commercially available (Sigma)) in DMSO was added HBTU and HOBT along with diisopropylethylamine and the reaction mixture was stirred overnight. The crude reaction mixture was purified directly by preparative HPLC on a reversed-phase C-18 column using a 0.1% trifluoroacetic acid (TFA) in acetonitrile/0.1% TFA in water gradient.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 2______________________________________  #STR21##   Compound R                    MS (parent ion)______________________________________12a     Ala-H                615  12b         Ala-N-Ac                                657  12c        Ala-Ala-Ala-N-Ac                        799.5  12d        Ala-Ser-Ala-Gly-Thr-Pro-Gly-Ala-N-Ac    1199                      (SEQ.ID.NO.: 12)______________________________________</pre>
    
    <heading>EXAMPLE 5</heading> <heading>In vitro Assay of Cytotoxicity of Peptidyl Derivatives of Doxorubicin</heading> <p>The cytotoxicities of the non-cleaveable oligopeptide-doxorubicin conjugates, prepared as described in Example 4, against a line of cells which is known to be killed by unmodified doxorubicin were assessed with an Alamar Blue assay. Specifically, cell cultures of LNCaP prostate tumor cells, which are a human metastatic prostate adenocarcinoma isolated from a needle biopsy of a lymph node (LNCaP.FGC: American Type Culture Collection, ATCC CRL 1740), or DuPRO cells in 96 well plates were diluted with medium containing various concentrations of a given conjugate (final plate well volume of 200 Œºl). The cells were incubated for 3 days at 37¬∞ C. and then 20 Œºl of Alamar Blue was added to the assay well. The cells were further incubated and the assay plates were read on a EL-310 ELISA reader at the dual wavelengths of 570 and 600 nm at 4 and 7 hours after addition of Alamar Blue. Relative percentage viability at the various concentration of conjugate tested was then calculated versus control (no conjugate) cultures. Cytotoxicities of unmodified doxorubicin and unmodified oligopeptide were also assessed. FIG. 3 shows the cytotoxicity data for a representative compound (Compound 12d).</p>
    <heading>EXAMPLE 6</heading> <heading>Assessment of Enzymatically Active PSA from LNCaP Cells</heading> <p>Enzymatic activity was demonstrated by incubating LNCaP serum free media (concentrated approximately 200 fold) with recombinant Senemogelin I protein. Approximately 0.5 Œºg of immunologically reactive PSA in concentrated conditioned media [determined by HYBRIDTECH (Tandem E) elisa] was mixed with approximately 3 Œºg of recombinant Semenogelin I and incubated for 4 hours at 37¬∞ C. At the end of the incubation, the digest mixture was analyzed by Western blot procedures. The results show that purified PSA from semen and PSA from LNCaP conditioned media generate identical proteolytic maps of the recombinant Semenogelin I protein. Thus, LNCap cells produce enzymatically active PSA. LNCaP are tumorigenic in nude mice and produce detectable levels of circulating PSA.</p>
    <heading>EXAMPLE 7</heading> <heading>Preparation of Cleavable Oligopeptide-Doxorubicin Conjugates</heading> <p>The derivatives of doxorubicin wherein an oligopeptide which is proteolytically cleaved by free PSA is covalently attached to the amine of the sugar moiety of the doxorubicin were prepared using the following general reaction: To a mixture of doxorubicin (Sigma) and the corresponding peptide (prepared by solid phase synthesis as described in Example 2) in DMSO was added HBTU and HOBT along with diisopropylethylamine and the reaction mixture stirred overnight. The crude reaction mixture was purified directly by preparative HPLC on a reversed-phase C-18 column using a 0.1% trifluoroacetic acid (TFA) in acetonitrile/0.1% TFA in water gradient. When reactive amine moieties were present on the peptide, such a functionality was typically protected as the fluorenylmethyloxycarbonyl adduct, which was removed by treatment with a secondary amine, such as piperidine and the like, subsequent to conjugation with doxirubicin. The instant conjugates have a structure of the general formula ##STR22## and may be represented by the phrase "Ac-peptide-DOX (3')." Conjugates prepared by this method are listed in FIG. 5.</p>
    <heading>EXAMPLE 8</heading> <heading>Assessment of the Recognition of Oligopeptide-Doxorubicin Conjugates by Free PSA</heading> <p>The conjugates prepared as described in Example 7 were individually dissolved in PSA digestion buffer (12 mM tris(hydroxymethyl)aminomethane pH8.0, 25 mM NaCl, 0.5 mM CaCl<sub>2</sub>) and the solution added to PSA at a molar ration of 100 to 1. The reaction is quenched after various reaction times by the addition of trifluoroacetic acid (TFA) to a final 1% (volume/volume). The quenched reaction was analyzed by HPLC on a reversed-phase C18 column using an aqueous 0.1% TFA/acetonitrile gradient. The results of the assessment are shown in FIG. 5.</p>
    <heading>EXAMPLE 9</heading> <heading>Assessment of the Cleavage of Oligopeptide-Doxorubicin Conjugates in Cell Conditioned Media</heading> <p>Cell conditioned serum-free MEMŒ± media (phenol red minus) was collected 3 days after the addition of the media to either LNCap or Dupro (prepared as described in J. Urology, 146:915-919 (1991)) cell lines. The media was concentrated 20 fold using an Amicon¬Æ Centriprep‚Ñ¢ concentrator with a 10,000 molecular weight cutoff. The LNCap conditioned media contained free PSA protein at, on average, approximately 100 ng/mL concentration as determined by the Tandem¬Æ-E PSA immunodetection kit (Hybritech¬Æ). There was no detectable free PSA in the Dupro cell conditioned media.</p>
    <p>100 ŒºL portions of concentrated conditioned media was mixed with 35 Œºg of a oligopeptide-doxorubicin conjugate prepared as described in Example 7 and the mixture was incubated at 37¬∞ C. for 0, 4 and 24 hour time points. The reactions were stopped by the addition of ZnCl<sub>2</sub> (to a 0.01M final concentration and analyzed by HPLC on a reversed-phase C18 column using an aqueous 0.1% TFA/acetonitrile gradient to determine the percentage of peptide-cytotoxic agent conjugate that had been digested. The results of the assessment are shown in FIG. 6.</p>
    <heading>EXAMPLE 10</heading> <heading>In vitro Assay of Cytotoxicity of Peptidyl Derivatives of Doxorubicin</heading> <p>The cytotoxicities of the cleaveable oligopeptide-doxorubicin conjugates, prepared as described in Example 7, against a line of cells which is known to be killed by unmodified doxorubicin was assessed with an Alamar Blue assay as described in Example 5. Specifically, cell cultures of LNCap prostate tumor cells or DuPRO cells in 96 well plates was diluted with medium containing various concentrations of a given conjugate (final plate well volume of 200 Œºl). The cells were incubated for 3 days at 37¬∞ C., 20 Œºl of Alamar Blue is added to the assay well. The cells were further incubated and the assay plates were read on a EL-310 ELISA reader at the dual wavelengths of 570 and 600 nm at 4 and 7 hours after addition of Alamar Blue. Relative percentage viability at the various concentration of conjugate tested was then calculated versus control (no conjugate) cultures. Cytotoxicities of the conjugates were also compared to the cytotoxicity of unmodified doxorubicin and unmodified oligopeptide assessed in the same assay. Results of this assay are shown in FIG. 7.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">__________________________________________________________________________#             SEQUENCE LISTING   - -  - - (1) GENERAL INFORMATION:   - -    (iii) NUMBER OF SEQUENCES: 146   - -  - - (2) INFORMATION FOR SEQ ID NO:1:   - -      (i) SEQUENCE CHARACTERISTICS:       (A) LENGTH: 462 amino - #acids       (B) TYPE: amino acid       (C) STRANDEDNESS: single       (D) TOPOLOGY: linear   - -     (ii) MOLECULE TYPE: peptide   - -    (iii) HYPOTHETICAL: NO   - -     (iv) ANTI-SENSE: NO   - -      (v) FRAGMENT TYPE: internal   - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:   - - Met Lys Pro Asn Ile Ile Phe Val Leu Ser Le - #u Leu Leu Ile LeuGlu  1               5   - #                10  - #                15  - - Lys Gln Ala Ala Val Met Gly Gln Lys Gly Gl - #y Ser Lys Gly Arg Leu        20      - #            25      - #            30  - - Pro Ser Glu Phe Ser Gln Phe Pro His Gly Gl - #n Lys Gly Gln His Tyr    35          - #        40          - #        45  - - Ser Gly Gln Lys Gly Lys Gln Gln Thr Glu Se - #r Lys Gly Ser Phe Ser50              - #    55              - #    60  - - Ile Gln Tyr Thr Tyr His Val Asp Ala Asn As - #p His Asp Gln Ser Arg 65                  - #70                  - #75                  - #80  - - Lys Ser Gln Gln Tyr Asp Leu Asn Ala Leu Hi - #s Lys Thr Thr Lys Ser            85  - #                90  - #                95  - - Gln Arg His Leu Gly Gly Ser Gln Gln Leu Le - #u His Asn Lys Gln Glu        100      - #           105      - #           110  - - Gly Arg Asp His Asp Lys Ser Lys Gly His Ph - #e His Arg Val Val Ile    115          - #       120          - #       125  - - His His Lys Gly Gly Lys Ala His Arg Gly Th - #r Gln Asn Pro Ser Gln130              - #   135              - #   140  - - Asp Gln Gly Asn Ser Pro Ser Gly Lys Gly Il - #e Ser Ser Gln Tyr Ser 145                 1 - #50                 1 - #55                 1 -#60   - - Asn Thr Glu Glu Arg Leu Trp Val His Gly Le - #u Ser Lys Glu GlnThr             165  - #               170  - #               175  - - Ser Val Ser Gly Ala Gln Lys Gly Arg Lys Gl - #n Gly Gly Ser Gln Ser        180      - #           185      - #           190  - - Ser Tyr Val Leu Gln Thr Glu Glu Leu Val Al - #a Asn Lys Gln Gln Arg    195          - #       200          - #       205  - - Glu Thr Lys Asn Ser His Gln Asn Lys Gly Hi - #s Tyr Gln Asn Val Val210              - #   215              - #   220  - - Glu Val Arg Glu Glu His Ser Ser Lys Val Gl - #n Thr Ser Leu Cys Pro 225                 2 - #30                 2 - #35                 2 -#40   - - Ala His Gln Asp Lys Leu Gln His Gly Ser Ly - #s Asp Ile Phe SerThr             245  - #               250  - #               255  - - Gln Asp Glu Leu Leu Val Tyr Asn Lys Asn Gl - #n His Gln Thr Lys Asn        260      - #           265      - #           270  - - Leu Asn Gln Asp Gln Gln His Gly Arg Lys Al - #a Asn Lys Ile Ser Tyr    275          - #       280          - #       285  - - Gln Ser Ser Ser Thr Glu Glu Arg Arg Leu Hi - #s Tyr Gly Glu Asn Gly290              - #   295              - #   300  - - Val Gln Lys Asp Val Ser Gln Ser Ser Ile Ty - #r Ser Gln Thr Glu Glu 305                 3 - #10                 3 - #15                 3 -#20   - - Lys Ala Gln Gly Lys Ser Gln Lys Gln Ile Th - #r Ile Pro Ser GlnGlu             325  - #               330  - #               335  - - Gln Glu His Ser Gln Lys Ala Asn Lys Ile Se - #r Tyr Gln Ser Ser Ser        340      - #           345      - #           350  - - Thr Glu Glu Arg Arg Leu His Tyr Gly Glu As - #n Gly Val Gln Lys Asp    355          - #       360          - #       365  - - Val Ser Gln Arg Ser Ile Tyr Ser Gln Thr Gl - #u Lys Leu Val Ala Gly370              - #   375              - #   380  - - Lys Ser Gln Ile Gln Ala Pro Asn Pro Lys Gl - #n Glu Pro Trp His Gly 385                 3 - #90                 3 - #95                 4 -#00   - - Glu Asn Ala Lys Gly Glu Ser Gly Gln Ser Th - #r Asn Arg Glu GlnAsp             405  - #               410  - #               415  - - Leu Leu Ser His Glu Gln Lys Gly Arg His Gl - #n His Gly Ser His Gly        420      - #           425      - #           430  - - Gly Leu Asp Ile Val Ile Ile Glu Gln Glu As - #p Asp Ser Asp Arg His    435          - #       440          - #       445  - - Leu Ala Gln His Leu Asn Asn Asp Arg Asn Pr - #o Leu Phe Thr450              - #   455              - #   460  - -  - - (2) INFORMATION FOR SEQ ID NO:2:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 15 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:  - - Gly Lys Gly Ile Ser Ser Gln Tyr Ser Asn Th - #r Glu Glu Arg Leu 1               5   - #                10  - #                15  - -  - - (2) INFORMATION FOR SEQ ID NO:3:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 11 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:  - - Asn Lys Ile Ser Tyr Gln Ser Ser Ser Thr Gl - #u 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:4:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 19 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:  - - Gly Glu Asn Gly Val Gln Lys Asp Val Ser Gl - #n Arg Ser Ile Tyr Ser 1               5   - #                10  - #                15  - - Gln Thr Glu  - -  - - (2) INFORMATION FOR SEQ ID NO:5:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 19 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:  - - Gly Glu Asn Gly Val Gln Lys Asp Val Ser Gl - #n Ser Ser Ile Tyr Ser 1               5   - #                10  - #                15  - - Gln Thr Glu  - -  - - (2) INFORMATION FOR SEQ ID NO:6:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 25 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:  - - Gly Arg Lys Ala Asn Lys Ile Ser Tyr Gln Se - #r Ser Ser Thr Glu Glu 1               5   - #                10  - #                15  - - Arg Arg Leu His Tyr Gly Glu Asn Gly        20      - #            25  - -  - - (2) INFORMATION FOR SEQ ID NO:7:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 8 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:  - - Ser Tyr Gln Ser Ser Ser Thr Glu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:8:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 9 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:  - - Ile Ser Tyr Gln Ser Ser Ser Thr Glu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:9:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:  - - Lys Ile Ser Tyr Gln Ser Ser Ser Thr Glu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:10:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:  - - Asn Lys Ile Ser Tyr Gln Ser Ser Ser Thr 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:11:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 12 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:  - - Ala Asn Lys Ile Ser Tyr Gln Ser Ser Ser Th - #r Glu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:12:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 8 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:  - - Ala Ser Ala Gly Thr Pro Gly Ala 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:13:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:  - - Asn Lys Ile Ser Tyr Gln Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:14:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 6 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:  - - Lys Ile Ser Tyr Gln Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:15:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 19 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (ix) FEATURE:      (A) NAME/KEY: Peptide      (B) LOCATION: 12      (D) OTHER INFORMATION: - #/note= "any natural amino acid"  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:  - - Gly Glu Asn Gly Val Gln Lys Asp Val Ser Gl - #n Xaa Ser Ile Tyr Ser 1               5   - #                10  - #                15  - - Gln Thr Glu  - -  - - (2) INFORMATION FOR SEQ ID NO:16:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 8 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:  - - Asn Lys Ile Ser Tyr Gln Ser Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:17:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 9 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:  - - Asn Lys Ile Ser Tyr Gln Ser Ser Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:18:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:  - - Ala Asn Lys Ile Ser Tyr Gln Ser Ser Ser 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:19:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:  - - Lys Ile Ser Tyr Gln Ser Ser Ser Thr Glu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:20:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 17 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:  - - Gln Leu Asp Asn Lys Ile Ser Tyr Gln Ser Se - #r Ser Thr His Gln Ser 1               5   - #                10  - #                15  - - Ser  - -  - - (2) INFORMATION FOR SEQ ID NO:21:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:  - - Asn Arg Ile Ser Tyr Gln Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:22:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:  - - Asn Lys Val Ser Tyr Gln Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:23:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 8 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: protein  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:  - - Asn Lys Met Ser Tyr Gln Ser Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:24:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 8 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:  - - Asn Lys Leu Ser Tyr Gln Ser Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:25:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 9 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:  - - Asn Lys Ile Thr Tyr Gln Ser Ser Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:26:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 9 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:  - - Asn Lys Ile Ser Phe Gln Ser Ser Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:27:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:  - - Asn Lys Ile Ser Trp Gln Ser Ser Ser Thr 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:28:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:  - - Asn Lys Ile Ser Tyr Asn Ser Ser Ser Thr 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:29:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:  - - Asn Lys Ile Ser Tyr Gln Thr Ser Ser Thr 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:30:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:  - - Asn Lys Ile Ser Tyr Gln Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:31:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 8 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:  - - Gln Lys Ile Ser Tyr Gln Ser Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:32:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 9 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:  - - Asn Arg Ile Thr Tyr Gln Ser Ser Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:33:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:  - - Asn Arg Ile Ser Phe Gln Ser Ser Ser Thr 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:34:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:  - - Gln Lys Ile Ser Tyr Gln Thr Ser Ser Thr 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:35:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:  - - Asn Arg Ile Ser Trp Gln Ser Ser Ser Thr 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:36:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:  - - Asn Arg Ile Ser Tyr Gln Thr Ser Ser Thr 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:37:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:  - - Asn Lys Ile Thr Tyr Gln Thr Ser Ser Thr 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:38:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:  - - Asn Lys Leu Ser Tyr Gln Thr Ser Ser Thr 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:39:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:  - - Gln Lys Leu Ser Tyr Gln Ser Ser Ser Thr 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:40:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:  - - Asn Arg Leu Ser Tyr Gln Thr Ser Ser Thr 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:41:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:  - - Asn Lys Val Ser Phe Gln Ser Ser Ser Thr 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:42:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:  - - Asn Arg Val Ser Trp Gln Ser Ser Ser Thr 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:43:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:  - - Gln Lys Val Ser Tyr Gln Ser Ser Ser Thr 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:44:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:  - - Asn Lys Ile Ser Tyr Gln Ser Ser Ser Thr 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:45:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 19 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:  - - Gly Glu Gln Gly Val Gln Lys Asp Val Ser Gl - #n Ser Ser Ile Tyr Ser 1               5   - #                10  - #                15  - - Gln Thr Glu  - -  - - (2) INFORMATION FOR SEQ ID NO:46:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 15 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:  - - Gly Lys Gly Ile Ser Ser Gln Tyr Ser Asn Th - #r Asp Glu Arg Leu 1               5   - #                10  - #                15  - -  - - (2) INFORMATION FOR SEQ ID NO:47:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 19 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:  - - Gly Glu Asn Gly Leu Gln Lys Asp Val Ser Gl - #n Ser Ser Ile Tyr Ser 1               5   - #                10  - #                15  - - Gln Thr Glu  - -  - - (2) INFORMATION FOR SEQ ID NO:48:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 19 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:  - - Gly Glu Asn Gly Val Asn Lys Asp Val Ser Gl - #n Ser Ser Ile Tyr Ser 1               5   - #                10  - #                15  - - Gln Thr Glu  - -  - - (2) INFORMATION FOR SEQ ID NO:49:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 19 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:  - - Gly Glu Asn Gly Val Gln Arg Asp Val Ser Gl - #n Arg Ser Ile Tyr Ser 1               5   - #                10  - #                15  - - Gln Thr Glu  - -  - - (2) INFORMATION FOR SEQ ID NO:50:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 19 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:  - - Gly Glu Asn Gly Val Gln Lys Asp Val Ser Gl - #n Lys Ser Ile Tyr Ser 1               5   - #                10  - #                15  - - Gln Thr Glu  - -  - - (2) INFORMATION FOR SEQ ID NO:51:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 19 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:  - - Gly Glu Asn Gly Val Gln Lys Asp Leu Ser Gl - #n Thr Ser Ile Tyr Ser 1               5   - #                10  - #                15  - - Gln Thr Glu  - -  - - (2) INFORMATION FOR SEQ ID NO:52:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 19 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:  - - Gly Glu Asn Gly Val Gln Lys Asp Val Ser Gl - #n Ser Ser Ile Phe Ser 1               5   - #                10  - #                15  - - Gln Thr Glu  - -  - - (2) INFORMATION FOR SEQ ID NO:53:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 19 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:  - - Gly Glu Asn Gly Val Gln Lys Asp Met Ser Gl - #n Ser Ser Ile Tyr Thr 1               5   - #                10  - #                15  - - Gln Thr Glu  - -  - - (2) INFORMATION FOR SEQ ID NO:54:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 19 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:  - - Gly Glu Asn Gly Val Gln Lys Asp Val Ser Gl - #n Arg Ser Ile Tyr Thr 1               5   - #                10  - #                15  - - Gln Thr Glu  - -  - - (2) INFORMATION FOR SEQ ID NO:55:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 19 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:  - - Gly Glu Asn Gly Val Gln Lys Asp Val Ser Gl - #n Ser Ser Ile Tyr Ser 1               5   - #                10  - #                15  - - Gln Ser Glu  - -  - - (2) INFORMATION FOR SEQ ID NO:56:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 19 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:  - - Gly Glu Asn Gly Val Gln Lys Asp Val Ser Gl - #n Arg Ser Ile Tyr Ser 1               5   - #                10  - #                15  - - Asn Thr Glu  - -  - - (2) INFORMATION FOR SEQ ID NO:57:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 15 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:  - - Gly Lys Ala Ile Ser Ser Gln Tyr Ser Asn Th - #r Glu Glu Arg Leu 1               5   - #                10  - #                15  - -  - - (2) INFORMATION FOR SEQ ID NO:58:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 15 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:  - - Gly Lys Gly Ile Ser Ser Gln Tyr Ser Asn Se - #r Glu Glu Arg Leu 1               5   - #                10  - #                15  - -  - - (2) INFORMATION FOR SEQ ID NO:59:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 15 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:  - - Gly Arg Gly Ile Ser Ser Gln Tyr Ser Asn Th - #r Glu Glu Arg Leu 1               5   - #                10  - #                15  - -  - - (2) INFORMATION FOR SEQ ID NO:60:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 15 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:  - - Gly Lys Gly Ile Thr Ser Gln Tyr Ser Asn Th - #r Glu Glu Arg Leu 1               5   - #                10  - #                15  - -  - - (2) INFORMATION FOR SEQ ID NO:61:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 15 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:  - - Gly Lys Gly Ile Ser Thr Gln Tyr Ser Asn Th - #r Glu Glu Arg Leu 1               5   - #                10  - #                15  - -  - - (2) INFORMATION FOR SEQ ID NO:62:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 15 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:  - - Gly Lys Gly Ile Ser Ser Asn Tyr Ser Asn Th - #r Glu Glu Arg Leu 1               5   - #                10  - #                15  - -  - - (2) INFORMATION FOR SEQ ID NO:63:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 15 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:  - - Ala Lys Gly Ile Ser Ser Gln Tyr Ser Asn Th - #r Glu Glu Arg Leu 1               5   - #                10  - #                15  - -  - - (2) INFORMATION FOR SEQ ID NO:64:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 15 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:  - - Gly Lys Gly Ile Ser Ser Gln Phe Ser Asn Th - #r Glu Glu Arg Leu 1               5   - #                10  - #                15  - -  - - (2) INFORMATION FOR SEQ ID NO:65:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 15 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:  - - Gly Lys Gly Ile Ser Ser Gln Tyr Thr Asn Se - #r Glu Glu Arg Leu 1               5   - #                10  - #                15  - -  - - (2) INFORMATION FOR SEQ ID NO:66:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 15 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:  - - Gly Lys Gly Ile Ser Ser Gln Tyr Ser Asn Se - #r Glu Glu Arg Leu 1               5   - #                10  - #                15  - -  - - (2) INFORMATION FOR SEQ ID NO:67:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 25 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:  - - Ser Gln Lys Ala Asn Lys Ile Ser Tyr Gln Se - #r Ser Ser Thr Glu Glu 1               5   - #                10  - #                15  - - Arg Arg Leu His Tyr Gly Glu Asn Gly        20      - #            25  - -  - - (2) INFORMATION FOR SEQ ID NO:68:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 8 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:  - - Ile Ser Tyr Gln Ser Ser Ser Thr 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:69:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 9 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:  - - Ala Asn Lys Ile Ser Tyr Gln Ser Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:70:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 12 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:  - - Ala Asn Lys Ile Ser Tyr Gln Ser Ser Ser Th - #r Leu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:71:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 12 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:  - - Ala Asn Gly Ile Ser Tyr Gln Ser Ser Ser Th - #r Glu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:72:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 12 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:  - - Ala Asn Pro Ile Ser Tyr Gln Ser Ser Ser Th - #r Glu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:73:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 12 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:  - - Ala Asn Lys Ile Ser Tyr Gln Ser Ala Ser Th - #r Glu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:74:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 12 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:  - - Ala Asn Lys Ile Ser Tyr Gln Ser Ser Lys Th - #r Glu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:75:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 11 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:  - - Ala Asn Lys Ile Ser Tyr Gln Ser Ser Thr Gl - #u 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:76:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 12 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (ix) FEATURE:      (A) NAME/KEY: Peptide      (B) LOCATION: 5      (D) OTHER INFORMATION: - #/label= d-serine           /note= - #"unnatural configuration of the amino acid"  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:  - - Ala Asn Lys Ile Ser Tyr Gln Ser Ser Ser Th - #r Glu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:77:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 12 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (ix) FEATURE:      (A) NAME/KEY: Peptide      (B) LOCATION: 4      (D) OTHER INFORMATION: - #/label= d-isoleucine           /note= - #"unnatural amino acid stereochemical configuration"  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:  - - Ala Asn Lys Ile Ser Tyr Gln Ser Ser Ser Th - #r Glu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:78:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 12 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:  - - Ala Asn Lys Ile Ser Tyr Gln Ser Ser Gln Th - #r Glu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:79:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 12 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:  - - Ala Asn Lys Ile Ser Tyr Gln Ser Ala Lys Th - #r Glu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:80:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 12 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (ix) FEATURE:      (A) NAME/KEY: Peptide      (B) LOCATION: 3      (D) OTHER INFORMATION: - #/label= d-lysine           /note= - #"unnatural amino acid stereochemical           configuratio - #n"  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:  - - Ala Asn Lys Ile Ser Tyr Gln Ser Ser Ser Th - #r Glu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:81:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:  - - Ala Asn Lys Ile Ser Tyr Gln Ser Thr Glu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:82:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:  - - Ala Asn Lys Ser Tyr Gln Ser Ser Thr Glu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:83:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:  - - Ala Asn Lys Ile Tyr Gln Ser Ser Thr Glu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:84:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 12 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:  - - Ala Asn Lys Ala Ser Tyr Gln Ser Ala Ser Th - #r Glu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:85:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 12 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:  - - Ala Asn Glu Ile Ser Tyr Gln Ser Ala Ser Th - #r Glu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:86:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:  - - Lys Ile Ser Tyr Gln Ser Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:87:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:  - - Ser Tyr Gln Ser Ser Thr Glu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:88:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:  - - Ser Tyr Gln Ser Ser Thr Leu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:89:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 8 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:  - - Ala Ser Tyr Gln Ser Ser Thr Glu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:90:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:  - - Glu Ile Ser Tyr Gln Ser Ser Ser Thr Glu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:91:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 12 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:  - - Ala Asn Glu Ile Ser Tyr Gln Ser Ser Ser Th - #r Glu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:92:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 12 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:  - - Ala Asn Lys Ile Ser Tyr Tyr Ser Ser Ser Th - #r Glu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:93:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 12 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:  - - Ala Asn Lys Ile Ser Tyr Tyr Ser Ala Ser Th - #r Glu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:94:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:  - - Ala Ser Tyr Gln Ser Ser Leu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:95:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:  - - Ala Asn Ser Tyr Gln Ser Ser Ser Thr Glu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:96:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 9 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:  - - Ala Ser Tyr Gln Ser Ser Ser Thr Glu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:97:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 8 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:  - - Ser Tyr Gln Ser Ser Ser Thr Glu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:98:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 11 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:  - - Ala Asn Lys Ala Ser Tyr Gln Ser Ala Ser Cy - #s 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:99:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 5 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:  - - Gln Ser Ser Thr Glu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:100:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 6 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:  - - Tyr Gln Ser Ser Thr Glu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:101:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 6 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:  - - Ser Gln Ser Ser Thr Glu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:102:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:  - - Ala Asn Lys Ile Ser Gln Ser Ser Thr Glu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:103:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 11 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (ix) FEATURE:      (A) NAME/KEY: Peptide      (B) LOCATION: 3      (D) OTHER INFORMATION: - #/label= unnatural           /note= - #"ornithine"  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:  - - Ala Asn Xaa Ile Ser Tyr Gln Ser Ser Thr Gl - #u 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:104:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (ix) FEATURE:      (A) NAME/KEY: Peptide      (B) LOCATION: 2      (D) OTHER INFORMATION: - #/label= unnatural           /note= - #"3,4-dichlorophenalanine"  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:  - - Ser Xaa Gln Ser Ser Thr Glu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:105:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (ix) FEATURE:      (A) NAME/KEY: Peptide      (B) LOCATION: 2      (D) OTHER INFORMATION: - #/label= unnatural           /note= - #"(3-pyridinyl)alanine"  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:  - - Ser Xaa Gln Ser Ser Thr Glu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:106:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:  - - Ser Lys Gln Ser Ser Thr Glu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:107:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:  - - Ser Tyr Gln Ser Ser Ser Leu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:108:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: protein  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (ix) FEATURE:      (A) NAME/KEY: Peptide      (B) LOCATION: 1      (D) OTHER INFORMATION: - #/label= unnatural           /note= - #"epsilon aminocaproic acid"  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:  - - Xaa Tyr Gln Ser Ser Ser Leu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:109:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 11 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (ix) FEATURE:      (A) NAME/KEY: Peptide      (B) LOCATION: 4      (D) OTHER INFORMATION: - #/label= unnatural           /note= - #"N-methylisoleucine"  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:  - - Ala Asn Lys Xaa Ser Tyr Gln Ser Ser Thr Gl - #u 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:110:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:  - - Ser Tyr Gln Ser Ser Thr Glu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:111:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 6 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:  - - Tyr Gln Ser Ser Thr Glu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:112:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:  - - Ser Tyr Lys Ser Ser Thr Glu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:113:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:  - - Ser Tyr Tyr Ser Ser Thr Glu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:114:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 6 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:  - - Ser Tyr Gln Ser Ser Leu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:115:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 6 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:  - - Ser Tyr Gln Ser Ser Leu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:116:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (ix) FEATURE:      (A) NAME/KEY: Peptide      (B) LOCATION: 1      (D) OTHER INFORMATION: - #/label= unnatural           /note= - #"2,3-diaminopropionic acid"  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:  - - Xaa Tyr Gln Ser Ser Ser Leu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:117:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 11 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:  - - Ala Asn Lys Ile Ser Tyr Gln Ser Ser Ser Th - #r 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:118:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 12 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:  - - Ala Asn Lys Ala Ser Tyr Gln Ser Ala Ser Th - #r Leu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:119:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 11 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:  - - Ala Asn Lys Ala Ser Tyr Gln Ser Ala Ser Le - #u 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:120:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 11 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:  - - Ala Asn Lys Ala Ser Tyr Gln Ser Ser Ser Le - #u 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:121:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 10 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:  - - Ala Asn Lys Ala Ser Tyr Gln Ser Ser Leu 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:122:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (ix) FEATURE:      (A) NAME/KEY: Peptide      (B) LOCATION: 7      (D) OTHER INFORMATION: - #/label= d-leucine           /note= - #"unnatural amino acid stereochemical           configuratio - #n"  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:  - - Ser Tyr Gln Ser Ser Thr Leu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:123:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 11 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:  - - Ala Asn Lys Ala Ser Tyr Ala Ser Ser Ser Le - #u 1               5   - #                10  - -  - - (2) INFORMATION FOR SEQ ID NO:124:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:  - - Lys Tyr Gln Ser Ser Ser Leu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:125:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:  - - Ser Tyr Gln Ser Ser Lys Leu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:126:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (ix) FEATURE:      (A) NAME/KEY: Peptide      (B) LOCATION: 7      (D) OTHER INFORMATION: - #/label= d-leucine           /note= - #"unnatural amino acid stereochemical           configuratio - #n"  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:  - - Ser Tyr Gln Ser Ser Lys Leu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:127:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:  - - Asn Lys Ile Ser Tyr Tyr Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:128:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:  - - Asn Lys Ala Ser Tyr Gln Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:129:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 5 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:  - - Ser Tyr Gln Ser Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:130:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 8 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:  - - Asn Lys Ile Ser Tyr Gln Ser Ala 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:131:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 8 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:  - - Ala Asn Lys Ile Ser Tyr Tyr Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:132:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 8 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:  - - Ala Asn Lys Ala Ser Tyr Gln Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:133:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 6 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:  - - Ser Tyr Gln Ser Ser Thr 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:134:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 6 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:  - - Ser Tyr Gln Ser Ser Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:135:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 6 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:  - - Ser Tyr Gln Ser Ser Leu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:136:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 9 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:  - - Ala Asn Lys Ile Ser Tyr Gln Ser Ala 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:137:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 9 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:  - - Ala Asn Lys Ile Ser Tyr Tyr Ser Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:138:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 9 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:  - - Ala Asn Lys Ile Ser Tyr Tyr Ser Ala 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:139:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 9 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:  - - Ala Asn Lys Ala Ser Tyr Gln Ser Ala 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:140:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 5 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:  - - Lys Tyr Gln Ser Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:141:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 5 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (ix) FEATURE:      (A) NAME/KEY: Peptide      (B) LOCATION: 1      (D) OTHER INFORMATION: - #/label= homoarginine  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:  - - Xaa Tyr Gln Ser Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:142:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 6 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:  - - Lys Tyr Gln Ser Ser Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:143:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 6 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (ix) FEATURE:      (A) NAME/KEY: Peptide      (B) LOCATION: 1      (D) OTHER INFORMATION: - #/label= homoarginine  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:  - - Xaa Tyr Gln Ser Ser Ser 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:144:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:  - - Ser Tyr Gln Ser Ser Ser Leu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:145:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (ix) FEATURE:      (A) NAME/KEY: Peptide      (B) LOCATION: 1      (D) OTHER INFORMATION: - #/label= homoarginine  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:  - - Xaa Tyr Gln Ser Ser Ser Leu 1               5  - -  - - (2) INFORMATION FOR SEQ ID NO:146:  - -      (i) SEQUENCE CHARACTERISTICS:      (A) LENGTH: 7 amino - #acids      (B) TYPE: amino acid      (C) STRANDEDNESS: single      (D) TOPOLOGY: linear  - -     (ii) MOLECULE TYPE: peptide  - -    (iii) HYPOTHETICAL: NO  - -     (iv) ANTI-SENSE: NO  - -      (v) FRAGMENT TYPE: internal  - -     (ix) FEATURE:      (A) NAME/KEY: Peptide      (B) LOCATION: 7      (D) OTHER INFORMATION: - #/label= norleucine  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:  - - Lys Tyr Gln Ser Ser Ser Leu 1               5__________________________________________________________________________</pre>
    
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4277466">US4277466</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 17, 1979</td><td class="patent-data-table-td patent-date-value">Jul 7, 1981</td><td class="patent-data-table-td ">Institut International De Pathologie Cellulaire Et Moleculaire</td><td class="patent-data-table-td ">Antileukemia agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4296105">US4296105</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 5, 1979</td><td class="patent-data-table-td patent-date-value">Oct 20, 1981</td><td class="patent-data-table-td ">Institut International De Pathologie Cellulaire Et Moleculaire</td><td class="patent-data-table-td ">Derivatives of doxorubicine, their preparation and use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4388305">US4388305</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 3, 1981</td><td class="patent-data-table-td patent-date-value">Jun 14, 1983</td><td class="patent-data-table-td ">Omnichem S.A.</td><td class="patent-data-table-td ">Less toxic than vincristine or vindesine</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4446122">US4446122</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 23, 1980</td><td class="patent-data-table-td patent-date-value">May 1, 1984</td><td class="patent-data-table-td ">Research Corporation</td><td class="patent-data-table-td ">Purified human prostate antigen</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4703107">US4703107</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 3, 1985</td><td class="patent-data-table-td patent-date-value">Oct 27, 1987</td><td class="patent-data-table-td ">Centre National De La Recherche Scientifique (Cnrs)</td><td class="patent-data-table-td ">Water-soluble acylated derivatives of peptides or amino acids, their preparation and their use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4753984">US4753984</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 9, 1986</td><td class="patent-data-table-td patent-date-value">Jun 28, 1988</td><td class="patent-data-table-td ">Centre National De La Recherche Scientifique (Cnrs)</td><td class="patent-data-table-td ">Water soluble macromolecular prodrugs, their preparation and their use as antitumor and antiparasite medicines</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4828831">US4828831</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Dec 12, 1986</td><td class="patent-data-table-td patent-date-value">May 9, 1989</td><td class="patent-data-table-td ">Omnichem</td><td class="patent-data-table-td ">New conjugates of vinblastine and its derivatives, process for preparing them and pharmaceutical compositions containing them</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4870162">US4870162</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 23, 1986</td><td class="patent-data-table-td patent-date-value">Sep 26, 1989</td><td class="patent-data-table-td ">Omnichem</td><td class="patent-data-table-td ">Conjugates of vinblastine, a process for their preparation and their use in therapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5024835">US5024835</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 3, 1989</td><td class="patent-data-table-td patent-date-value">Jun 18, 1991</td><td class="patent-data-table-td ">Ire-Celltarg S.A.</td><td class="patent-data-table-td ">Conjugates of a vinca derivative carrying a detergent chain in the C-3 position</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5030620">US5030620</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 13, 1989</td><td class="patent-data-table-td patent-date-value">Jul 9, 1991</td><td class="patent-data-table-td ">Omnichem</td><td class="patent-data-table-td ">Vinblastine derivatives, and pharmaceutical compositions containing them</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5220001">US5220001</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 22, 1990</td><td class="patent-data-table-td patent-date-value">Jun 15, 1993</td><td class="patent-data-table-td ">Zaidan Hojim Biseibutsu Dong-A Pharm Co.</td><td class="patent-data-table-td ">Anthracycline glycoside derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5288612">US5288612</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 3, 1991</td><td class="patent-data-table-td patent-date-value">Feb 22, 1994</td><td class="patent-data-table-td ">The Scripps Research Institute</td><td class="patent-data-table-td ">Assay methods for detecting serum proteases, particularly activated protein C</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5349066">US5349066</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 8, 1992</td><td class="patent-data-table-td patent-date-value">Sep 20, 1994</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Bifunctional linking compounds, conjugates and methods for their production</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5391723">US5391723</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 16, 1993</td><td class="patent-data-table-td patent-date-value">Feb 21, 1995</td><td class="patent-data-table-td ">Neorx Corporation</td><td class="patent-data-table-td ">Oligonucleotide conjugates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5599686">US5599686</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 28, 1994</td><td class="patent-data-table-td patent-date-value">Feb 4, 1997</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">Oligopeptide comprising sequence of amino acids recognized and selectively proteolytically cleaved by free prostate specific antigen</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5866679">US5866679</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 6, 1995</td><td class="patent-data-table-td patent-date-value">Feb 2, 1999</td><td class="patent-data-table-td ">Merck &amp; Co., Inc.</td><td class="patent-data-table-td ">Peptides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0126344A2?cl=en">EP0126344A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 2, 1984</td><td class="patent-data-table-td patent-date-value">Nov 28, 1984</td><td class="patent-data-table-td ">Abbott Laboratories</td><td class="patent-data-table-td ">Tripeptide esters of therapeutic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0554708A1?cl=en">EP0554708A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 19, 1993</td><td class="patent-data-table-td patent-date-value">Aug 11, 1993</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">Thioether conjugates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0590530A2?cl=en">EP0590530A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 24, 1993</td><td class="patent-data-table-td patent-date-value">Apr 6, 1994</td><td class="patent-data-table-td ">BEHRINGWERKE Aktiengesellschaft</td><td class="patent-data-table-td ">Fusion proteins for prodrug-activation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="http://www.google.com/url?id=r7hRBAABERAJ&amp;q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DFR%26NR%3D2678274A1%26KC%3DA1%26FT%3DD&amp;usg=AFQjCNGJpX8hcftia2rSqMSb5-n4UMZIUw">FR2678274A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td patent-date-value"></td><td class="patent-data-table-td "> </td><td class="patent-data-table-td citation-no-title">Title not available</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1992001936A1?cl=en">WO1992001936A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 22, 1991</td><td class="patent-data-table-td patent-date-value">Feb 6, 1992</td><td class="patent-data-table-td ">Hans Lilja</td><td class="patent-data-table-td ">Assay of free and complexed prostate-specific antigen (psa)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1994010343A1?cl=en">WO1994010343A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 27, 1993</td><td class="patent-data-table-td patent-date-value">May 11, 1994</td><td class="patent-data-table-td ">Univ Jefferson</td><td class="patent-data-table-td ">Methods of detecting micrometastasis of prostate cancer</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1994020114A1?cl=en">WO1994020114A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 11, 1994</td><td class="patent-data-table-td patent-date-value">Sep 15, 1994</td><td class="patent-data-table-td ">Univ Texas</td><td class="patent-data-table-td ">Anthracyclines with unusually high activity against cells resistant to doxorubicin and its analogs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1995030758A1?cl=en">WO1995030758A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 9, 1995</td><td class="patent-data-table-td patent-date-value">Nov 16, 1995</td><td class="patent-data-table-td ">Hybritech Inc</td><td class="patent-data-table-td ">Recombinant hk2 polypeptide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1996005863A1?cl=en">WO1996005863A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 21, 1995</td><td class="patent-data-table-td patent-date-value">Feb 29, 1996</td><td class="patent-data-table-td ">Wallone Region</td><td class="patent-data-table-td ">Compounds, pharmaceutical composition and diagnostic device comprising same and their use</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Anal. Biochem., vol. 193, pp. 248 255 (1991), by Harnois Pontoni, et al.</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Anal. Biochem., vol. 193, pp. 248-255 (1991), by Harnois-Pontoni, et al.</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Barnett, C.J., et al., Structure Activity Relationships of Dimeric Catharanthus Alkaloids. 1. Deacetylyinblastine Amide (Vindesine) Sulfate, Jour. Med. Chem., vol. 21, No. 1 (1978).</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Barnett, C.J., et al., Structure-Activity Relationships of Dimeric Catharanthus Alkaloids. 1. Deacetylyinblastine Amide (Vindesine) Sulfate, Jour. Med. Chem., vol. 21, No. 1 (1978).</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Eur. J. Biochem, vol. 95, pp. 115 119 (1979), by Pozsgay, et al.</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Eur. J. Biochem, vol. 95, pp. 115-119 (1979), by Pozsgay, et al.</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Eur. J. Biochem., vol. 194, pp. 755 763 (1990), by Christensson, et al.</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Eur. J. Biochem., vol. 194, pp. 755-763 (1990), by Christensson, et al.</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">J. Med. Chem, vol. 26, pp. 633 638 (1983), by Chakravarty, et al.</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">J. Med. Chem, vol. 26, pp. 633-638 (1983), by Chakravarty, et al.</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">J. Med. Chem., vol. 34, pp. 3029 3035 (1991), by Mayer, et al.</td></tr><tr><td class="patent-data-table-td ">12</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">J. Med. Chem., vol. 34, pp. 3029-3035 (1991), by Mayer, et al.</td></tr><tr><td class="patent-data-table-td ">13</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">J. of Med. Chem, vol. 26, No. 5, pp. 638 644 (1983), by Chakravarty, et al.</td></tr><tr><td class="patent-data-table-td ">14</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">J. of Med. Chem, vol. 26, No. 5, pp. 638-644 (1983), by Chakravarty, et al.</td></tr><tr><td class="patent-data-table-td ">15</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lilja, H. and Lundwall, A., "<a href='http://scholar.google.com/scholar?q="Molecular+cloning+of+epididymal+and+seminal+vesicular+transcripts+encoding+a+semenogelin-related+protein%2C"'>Molecular cloning of epididymal and seminal vesicular transcripts encoding a semenogelin-related protein,</a>" Proc. Natl. Acad, Sci. USA, Biochemistry, vol. 89, pp. 4559-4563 (1992).</td></tr><tr><td class="patent-data-table-td ">16</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Lilja, H. and Lundwall, A., Molecular cloning of epididymal and seminal vesicular transcripts encoding a semenogelin related protein, Proc. Natl. Acad, Sci. USA, Biochemistry , vol. 89, pp. 4559 4563 (1992).</td></tr><tr><td class="patent-data-table-td ">17</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lilja, H., et al., "<a href='http://scholar.google.com/scholar?q="Semenogelin%2C+the+Predominant+Protein+in+Human+Semen%2C"'>Semenogelin, the Predominant Protein in Human Semen,</a>" The Jour. of Biol. Chem., vol. 264, No. 3, pp. 1894-1900 (1989).</td></tr><tr><td class="patent-data-table-td ">18</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Lilja, H., et al., Semenogelin, the Predominant Protein in Human Semen, The Jour. of Biol. Chem., vol. 264, No. 3, pp. 1894 1900 (1989).</td></tr><tr><td class="patent-data-table-td ">19</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Proc. Natl. Acad. Sci. USA, vol. 83, pp. 3166 3170 (1986) Biochemistry, by Watt, et al.</td></tr><tr><td class="patent-data-table-td ">20</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Proc. Natl. Acad. Sci. USA, vol. 83, pp. 3166-3170 (1986) Biochemistry, by Watt, et al.</td></tr><tr><td class="patent-data-table-td ">21</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Rao, K.S.P.B., et al., Vinblastin 23 oyl Amino Acid Derivatives: Chemistry, Physiochemical Data, Toxicity, and Antitumor Activities against P388 and L1210 Leukemias, Jour. Med. Chem. , vol. 28, pp. 1079 1088 (1985).</td></tr><tr><td class="patent-data-table-td ">22</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Rao, K.S.P.B., et al., Vinblastin-23-oyl Amino Acid Derivatives: Chemistry, Physiochemical Data, Toxicity, and Antitumor Activities against P388 and L1210 Leukemias, Jour. Med. Chem., vol. 28, pp. 1079-1088 (1985).</td></tr><tr><td class="patent-data-table-td ">23</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Trail, P.A., et al., Cure of Xenografted Human Carcinomas by BR96 Doxorubicin Immunoconjugates, Science, vol. 261, pp. 212 215 (1993).</td></tr><tr><td class="patent-data-table-td ">24</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Trail, P.A., et al., Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates, Science, vol. 261, pp. 212-215 (1993).</td></tr><tr><td class="patent-data-table-td ">25</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Willner, D. et al., (6 Maleimidocaproyl)hydrazone of Doxorubicin A New Derivative for the Preparation of Immunoconjugates of Doxorubicin, Bioconjugate Chem., vol. 4, pp. 521 527 (1993).</td></tr><tr><td class="patent-data-table-td ">26</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Willner, D. et al., (6-Maleimidocaproyl)hydrazone of Doxorubicin--A New Derivative for the Preparation of Immunoconjugates of Doxorubicin, Bioconjugate Chem., vol. 4, pp. 521-527 (1993).</td></tr><tr><td class="patent-data-table-td ">27</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Yu, H., et al., Immunoreactive Prostate Specific Antigen Levels in Female and Male Breast Tumors and its Association with Steroid Hormone Receptors and Patient Age, Clinical Biochemistry , vol. 27, pp. 75 79 (1994).</td></tr><tr><td class="patent-data-table-td ">28</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Yu, H., et al., Immunoreactive Prostate-Specific Antigen Levels in Female and Male Breast Tumors and its Association with Steroid Hormone Receptors and Patient Age, Clinical Biochemistry, vol. 27, pp. 75-79 (1994).</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6649587">US6649587</a></td><td class="patent-data-table-td patent-date-value">Apr 27, 2000</td><td class="patent-data-table-td patent-date-value">Nov 18, 2003</td><td class="patent-data-table-td ">Slil Biomedical Corporation</td><td class="patent-data-table-td ">Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6809176">US6809176</a></td><td class="patent-data-table-td patent-date-value">May 6, 2002</td><td class="patent-data-table-td patent-date-value">Oct 26, 2004</td><td class="patent-data-table-td ">Slil Biomedical, Corporation</td><td class="patent-data-table-td ">Compounds for use in treatment of cancer</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7037898">US7037898</a></td><td class="patent-data-table-td patent-date-value">Nov 9, 2001</td><td class="patent-data-table-td patent-date-value">May 2, 2006</td><td class="patent-data-table-td ">Laregion Wallone</td><td class="patent-data-table-td ">Tumor-activated prodrug compounds and treatment</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7115573">US7115573</a></td><td class="patent-data-table-td patent-date-value">Jun 11, 2001</td><td class="patent-data-table-td patent-date-value">Oct 3, 2006</td><td class="patent-data-table-td ">Medarex, Inc.</td><td class="patent-data-table-td ">Prodrug compounds with an isoleucine</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7148349">US7148349</a></td><td class="patent-data-table-td patent-date-value">Oct 31, 2003</td><td class="patent-data-table-td patent-date-value">Dec 12, 2006</td><td class="patent-data-table-td ">Metabasis Therapeutics, Inc.</td><td class="patent-data-table-td ">Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7151092">US7151092</a></td><td class="patent-data-table-td patent-date-value">Oct 31, 2003</td><td class="patent-data-table-td patent-date-value">Dec 19, 2006</td><td class="patent-data-table-td ">Metabasis Therapeutics, Inc.</td><td class="patent-data-table-td ">Cytarabine monophosphate prodrugs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7253207">US7253207</a></td><td class="patent-data-table-td patent-date-value">Aug 2, 2004</td><td class="patent-data-table-td patent-date-value">Aug 7, 2007</td><td class="patent-data-table-td ">Cellgate, Inc.</td><td class="patent-data-table-td ">Quinones as disease therapies</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7329507">US7329507</a></td><td class="patent-data-table-td patent-date-value">Sep 29, 2006</td><td class="patent-data-table-td patent-date-value">Feb 12, 2008</td><td class="patent-data-table-td ">Medarex, Inc.</td><td class="patent-data-table-td ">Linking oligopeptide to a stabilizing group, linking the oligopeptide to a therapeutic agent, testing if the conjugate is cleavable by Thimet oligopeptidase</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7390629">US7390629</a></td><td class="patent-data-table-td patent-date-value">Mar 8, 2006</td><td class="patent-data-table-td patent-date-value">Jun 24, 2008</td><td class="patent-data-table-td ">La Region Wallonne</td><td class="patent-data-table-td ">Tumor-activated prodrug compounds and treatment</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7498320">US7498320</a></td><td class="patent-data-table-td patent-date-value">Sep 28, 2006</td><td class="patent-data-table-td patent-date-value">Mar 3, 2009</td><td class="patent-data-table-td ">Metabasis Therapeutics, Inc.</td><td class="patent-data-table-td ">Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7553826">US7553826</a></td><td class="patent-data-table-td patent-date-value">Oct 18, 2006</td><td class="patent-data-table-td patent-date-value">Jun 30, 2009</td><td class="patent-data-table-td ">Metabasis Therapeutics, Inc.</td><td class="patent-data-table-td ">Cytarabine monophosphate prodrugs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7618789">US7618789</a></td><td class="patent-data-table-td patent-date-value">Apr 3, 2002</td><td class="patent-data-table-td patent-date-value">Nov 17, 2009</td><td class="patent-data-table-td ">The United States Of America As Represented By The Secretary Of Department Of Health And Human Services</td><td class="patent-data-table-td ">Use of semenogelin in the diagnosis, prognosis and treatment of cancer</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7696313">US7696313</a></td><td class="patent-data-table-td patent-date-value">Jan 16, 2008</td><td class="patent-data-table-td patent-date-value">Apr 13, 2010</td><td class="patent-data-table-td ">Medarex, Inc.</td><td class="patent-data-table-td ">Prodrug compounds with isoleucine</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7718614">US7718614</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 28, 2006</td><td class="patent-data-table-td patent-date-value">May 18, 2010</td><td class="patent-data-table-td ">Kurume University</td><td class="patent-data-table-td ">Combination therapy of peptide vaccination and estramustine treatment</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7745395">US7745395</a></td><td class="patent-data-table-td patent-date-value">Sep 17, 2007</td><td class="patent-data-table-td patent-date-value">Jun 29, 2010</td><td class="patent-data-table-td ">University of Victoria Innovatiion and Development Corporation</td><td class="patent-data-table-td ">Recombinant protease comprising prostate-specific protease cleavage site and deficient in furin cleavage site for use as therapeutic agent in treatment of cell proliferative disorders; antitumor agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7838266">US7838266</a></td><td class="patent-data-table-td patent-date-value">May 27, 2010</td><td class="patent-data-table-td patent-date-value">Nov 23, 2010</td><td class="patent-data-table-td ">University Of Victoria Innovation And Development Corporation</td><td class="patent-data-table-td ">A purified pro-cytolytic peptide; used to treat localized and metastatic prostate cancer; administered intratumorally and/or intraprostatically</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7951772">US7951772</a></td><td class="patent-data-table-td patent-date-value">Jun 10, 2008</td><td class="patent-data-table-td patent-date-value">May 31, 2011</td><td class="patent-data-table-td ">La Region Wallonne</td><td class="patent-data-table-td ">Tumor-activated prodrug compounds and treatment</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc530/defs530.htm&usg=AFQjCNEOd3srpZKCSH0W93D5fiJ4_0S25w#C530S322000">530/322</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc530/defs530.htm&usg=AFQjCNEOd3srpZKCSH0W93D5fiJ4_0S25w#C530S328000">530/328</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc530/defs530.htm&usg=AFQjCNEOd3srpZKCSH0W93D5fiJ4_0S25w#C530S329000">530/329</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc530/defs530.htm&usg=AFQjCNEOd3srpZKCSH0W93D5fiJ4_0S25w#C530S326000">530/326</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc530/defs530.htm&usg=AFQjCNEOd3srpZKCSH0W93D5fiJ4_0S25w#C530S324000">530/324</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12Q0001370000">C12Q1/37</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=G01N0033566000">G01N33/566</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07K0017080000">C07K17/08</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0043000000">A61P43/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07K0014470000">C07K14/47</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07K0007060000">C07K7/06</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0038000000">A61K38/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0035000000">A61P35/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0047480000">A61K47/48</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07K0007080000">C07K7/08</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0038080000">A61K38/08</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07H0015240000">C07H15/24</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031195000">A61K31/195</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0013080000">A61P13/08</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=G01N0033574000">G01N33/574</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K47/48238">A61K47/48238</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07K14/47">C07K14/47</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K38/00">A61K38/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=r7hRBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K47/48338">A61K47/48338</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">C07K14/47</span>, <span class="nested-value">A61K47/48R4</span>, <span class="nested-value">A61K47/48R</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Dec 25, 2012</td><td class="patent-data-table-td ">FP</td><td class="patent-data-table-td ">Expired due to failure to pay maintenance fee</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20121107</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Nov 7, 2012</td><td class="patent-data-table-td ">LAPS</td><td class="patent-data-table-td ">Lapse for failure to pay maintenance fees</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 18, 2012</td><td class="patent-data-table-td ">REMI</td><td class="patent-data-table-td ">Maintenance fee reminder mailed</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Apr 17, 2008</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Apr 3, 2007</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">THE PATENTABILITY OF CLAIMS 1-8 IS CONFIRMED.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Nov 14, 2006</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20060502</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 20, 2004</td><td class="patent-data-table-td ">SULP</td><td class="patent-data-table-td ">Surcharge for late payment</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 20, 2004</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">May 26, 2004</td><td class="patent-data-table-td ">REMI</td><td class="patent-data-table-td ">Maintenance fee reminder mailed</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 27, 1997</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">MERCK &amp; CO., INC., NEW JERSEY</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DEFEO-JONES, DEBORAH;FENG, DONG-MEI;GARSKY, VICTOR M.;AND OTHERS;REEL/FRAME:008778/0126</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">19970606</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U2uoiXtJtjjK8UNAWqvC9mQ8m6ESg\u0026id=r7hRBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U3OAk-HihZdoEuSnWL52PljT-K2yA\u0026id=r7hRBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U0iz3FG0Ho0wGkGoiW6Q4nC2hR6Rw","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Peptides.pdf?id=r7hRBAABERAJ\u0026output=pdf\u0026sig=ACfU3U0NSVILxwP2uAHrlczofw5uaFi8Xw"},"sample_url":"http://www.google.com/patents/reader?id=r7hRBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>